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The small ubiquitin-related modifier (SUMO) regulates nearly every aspect of cellular 
function, from gene expression in the nucleus to ion transport at the plasma 
membrane. As such, misregulation of SUMO pathway enzymes are implicated in 
human cancers, neurodegeneration and inflammatory diseases, among others. 
Despite this knowledge, many questions remain unanswered, including, how can one 
~15kDa protein contribute to so many various and fundamentally different cellular 
functions and diseases? And, can we efficaciously target the SUMO pathway for 
treatment of associated diseases? If so, how might we identify the best patients to 
treat with such therapies? The work presented in this thesis uses a multi-faceted 
approach to address these questions. First, we dive into an exploration of the five 
SUMO paralogs (SUMO1-5) to understand how they can collectively regulate such 
diverse biological functions. One potential explanation is that the paralogs have unique 
and non-redundant cellular functions, though comprehensive evidence to support this 
was lacking. We therefore performed a systematic analysis of the literature, SUMO 
paralog expression in various human tissues, and CRISPR paralog knock-out cell 
lines, which each provided evidence for tissue and paralog-specific functions. Analysis 
of the knockout cell lines revealed non-redundant roles for the SUMO1 and SUMO2 
paralogs in regulating responses to various cellular stressors, nuclear body integrity, 
gene expression, and cellular morphology. Collectively, this work defines unique roles 
for the paralogs in diverse cellular processes, thus shedding light on how one pathway 
can be implicated in various cellular functions and diseases, and simultaneously 
providing a foundation for the development of precise SUMO paralog-targeting 
therapies. To aid in the selection of patients for treatment with such therapies, we 
developed a bioinformatics workflow to analyze the expression levels of SUMO 
 iii 
pathway enzymes in cancerous versus normal tissues. We present a published 
example of this workflow where we revealed that expression levels of the SENP1 
SUMO protease are unchanged in pancreatic cancer, thus indicating that SENP1 is 
not a predictive biomarker for this particular disease. Together, with our work on 
paralog-specific functions, we have provided insights essential for realizing the full 
therapeutic potential of the SUMO pathway.       
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Introduction to Ubiquitin and Ubiquitin-like Proteins 
 
 
A curious protein with two N-termini but only a single C-terminus was discovered in 
the mid-1970’s (1). This unusual Y-shaped protein was not an antibody, but a histone 
H2A protein that was covalently attached to a 76-amino acid polypeptide called 
ubiquitin. Ubiquitin has since become the classic example of a protein that through 
covalent attachment to other proteins, functions as a post-translational modification 
(PTM). PTMs greatly expand the diversity and functional capabilities of target proteins, 
and modification by ubiquitin is no exception. Although ubiquitin was first described as 
a signal for targeting proteins for proteasomal degradation, our understanding of its 
signaling capacity has grown to include regulation of the cell cycle, cellular stress 
response, DNA repair, protein synthesis and transcriptional regulation, among others 
(1, 2). The discovery of ubiquitin as a PTM has led to the subsequent identification of 
approximately a dozen novel ubiquitin-like proteins (UBLs) (3). There are two broadly 
defining characteristics of UBLs: they are reversibly conjugated onto lysine residues 
of target proteins through an enzymatic cascade, and they share a similar 3-D 
architecture. Crystal structures of ubiquitin and UBLs have revealed that they have a 
distinctive 3-D structure defined as a beta-grasp fold. This name comes from 5 anti-
parallel beta-strands that appear to “grasp” a single helical structure (3, 4). One such 
UBL, the small ubiquitin-related modifier (SUMO), is the focus of the work presented 






Introduction to the SUMO Pathway 
 
SUMOs are conserved throughout all eukaryotes, from single-celled yeast to humans 
and plants. They function as post-translational protein modifications in a reversible 
process called sumoylation. Like ubiquitin, they modify thousands of proteins and 
thereby regulate nearly every aspect of cellular function, from control of gene 
expression and genome integrity in the nucleus, to mitochondrial fission and ion 
channel activity in the cytoplasm (3, 5). Like most UBLs, SUMOs are covalently 
conjugated onto the lysine residues of target proteins through an E1, E2, E3 enzymatic 
cascade, and can be removed by proteases (Figure 1A). Unlike ubiquitin, of which 
there is a single modifier, the human genome encodes for five distinct SUMO paralogs 
(SUMO1-5) that have varying sequence homology (Figure 1B). These divergent 
sequences impart the paralogs with unique molecular features that raise the intriguing 
question about whether the SUMO paralogs have unique and non-redundant 
functions. If the paralogs do have unique functions, what are they and what is the 
overall significance? These questions are partly the focus of my thesis work and will 
be explored in Chapters 2 and 3, following a general introduction to sumoylation and 
the SUMO pathway. 
 
SUMO Conjugation  
 
When SUMO was first discovered 25 years ago, it was described based on its striking 
similarities to ubiquitin (6, 7). Like ubiquitin, SUMO is first produced as an immature 
precursor protein with a C-terminal peptide extension is that cleaved to expose a 
conserved di-glycine motif, which is required for activation. The cleaved (mature) 
protein is activated by an ATP-requiring heterodimeric E1 enzyme, SAE1-UBA2. The 
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E1 adenylates the exposed C-terminal glycine residue to form a high energy thioester 
intermediate between SUMO and the catalytic cysteine of the E1 (8). SUMO is then 
transferred to the active site cysteine of the sole SUMO E2 conjugating enzyme, Ubc9 
(3, 9). Ubc9 can then either directly conjugate SUMO onto target proteins, or transfer 
SUMO to an E3 ligating enzyme, which facilitates ligation of SUMOs onto target 
proteins. The most well-characterized E3 ligases include the Protein Inhibitor of STAT 
(PIAS) family of RING-related proteins, and RANBP2 (10).  
 
While the conjugation pathway is mostly analogous to ubiquitylation, the number of 
involved enzymes varies greatly. For instance, the human ubiquitin conjugation 
pathway has two E1s, 35 E2s and more than 300 E3 ligases, with some estimates 
ranging up to 700 E3s (11, 12). Of note, the hundreds of ubiquitin E3 ligases are 
required to determine target protein selection and specificity. In contrast, the SUMO 
pathway consists of a single E1 activating enzyme, a single E2 conjugating enzyme 
and approximately a dozen E3 ligating enzymes that can enhance the sumoylation 
reaction but have broad substrate specificity (Figure 2) (13-15). This relative simplicity 
raises the question of whether sumoylation may be a less complex and diverse PTM 
as compared to ubiquitylation. 
 
Ubiquitin and SUMO are similarly conjugated onto lysine residues of target proteins. 
Interestingly, although the ubiquitin pathway has been studied quite extensively, there 
is no clear consensus motif for ubiquitin conjugation, though it is often mapped to 
intrinsically disordered regions of target proteins (16). SUMOs, however, have a well-
defined consensus motif, ψKxE, where ψ is a bulky hydrophobic residue (such as 
isoleucine, leucine or valine), K is the target lysine residue, x is any amino acid, and E 
is the negatively charged glutamic acid residue (17). This consensus motif facilitates 
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interactions between the target protein and Ubc9 (17), and proteomics studies suggest 
that approximately 70% of SUMO-modified lysines are within this motif (18). 
Intriguingly, sumoylation appears to become more promiscuous under conditions of 
stress, such as proteasomal inhibition and heat shock, as exemplified by the finding 





Modification by both ubiquitin and SUMO can similarly be reversed through the 
catalytic activity of isopeptidases. Humans express 6 SUMO-specific proteases, 
SENP1-3 and SENP5-7 (20). Of note, SENP stands for Sentrin-specific protease, 
because SUMO was also named Sentrin after the discovery that it functioned similarly 
to a Sentry. In this case, the Sentry was guarding the cell death pathway based on the 
finding that SUMO binds to the death domain of Fas (21). Similarly, the proteases are 
guards of the pool of activated and free SUMOs. This is because SENPs cleave the 
C-terminal peptide extension of precursor SUMOs to reveal the di-glycine motif 
needed for activation, and also cleave the covalent isopeptide bond formed between 
SUMOs and substrate proteins (22).  
 
SENPs have conserved C-terminal active site cysteines, but divergent N-terminal 
domains that our lab and others have shown determine unique subcellular 
localizations and interacting partners (Figure 3) (20, 23-27). Interestingly, evaluation 
of evolutionary sequence relationships between the SENPs reveals pairwise 
similarities between SENP1-SENP2, SENP3-SENP5, and SENP6 -SENP7, 
suggesting both overlapping and unique functions of the SENPs (20). Consistent with 
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this, SENP1 and SENP2 both localize to the nucleus and to nuclear pores (28), 
however they regulate sumoylation uniquely during mitosis (24). Furthermore, work 
from our lab has found that SENP2 uniquely localizes to cytoplasmic membranes, 
suggesting a unique role for SENP2 in regulating sumoylation at such membranes 
(29). Moreover, SENP3 and SENP5 localize to the nucleolus, where SENP3 regulates 
ribosome biogenesis and SENP5 is involved in mitochondrial fragmentation during 
mitosis (22, 30, 31). Lastly, SENP6 and SENP7 predominately localize to the 
nucleoplasm, where SENP6 is required for inner kinetochore assembly during mitosis 
(20, 32).   
 
In addition to their involvement in regulating various essential cellular processes, 
SENPs also display SUMO paralog preferences. For instance, SENP1 and SENP2 
are the only SENPs that remove the SUMO1 C-terminal peptide extension, although 
they can also process SUMO2 and SUMO3 (20). However, SENP2 is more efficient 
than SENP1 at processing SUMO2 and SUMO3 (33). Moreover, the SENPs display 
paralog-specific preferences for cleavage of isopeptide bonds between the SUMO 
paralogs and target proteins, as discussed more thoroughly in Chapter 2.  
 
Taken together, SENPs are critical regulators of the SUMO pathway. They regulate 
the pool of active SUMO, and spatiotemporally remove SUMO from target proteins 
(20). To that end, misregulation of SENPs are implicated in numerous cancers, and 
have thus become therapeutic targets as well as inspiration for prognostic biomarkers, 
as discussed in more detail at the end of this chapter (15, 34). In Chapter 4, I also 
present my published work assessing to utility of SENP1 as a biomarker for pancreatic 





Perhaps one of the most significant differences between the ubiquitin and SUMO 
pathways is in the complexity of the modifiers themselves. In contrast to the single 
ubiquitin protein, humans express multiple SUMO proteins, SUMO1-5. The five SUMO 
paralogs contain a unique unstructured N-terminal tail that is not present in ubiquitin 
(36). As such, although “small” is in their name, SUMOs are actually bigger than 
ubiquitin and average approximately 101 amino acids in length, as compared to the 
76 amino acids of ubiquitin. Similar to ubiquitin, SUMO paralogs are produced as 
immature precursor proteins. After processing by SENPs to remove the C-terminal 
peptide extensions, they have varying homologies. For instance, SUMO2 and SUMO3 
share ~97% peptide sequence identity and are often referred to as SUMO2/3. 
Interestingly, although SUMO2 and SUMO3 only differ by 3 amino acids in the N-
terminus, these paralogs have unique biochemical features, which will be discussed 
in the next chapter (37). In contrast, SUMO1 only shares ~45% sequence identity with 
SUMO2/3. Moreover, SUMO4 shares 85% sequence identity with SUMO2/3 and 
SUMO5 is the most similar paralog to SUMO1, with 88% shared homology (Figure 
1B).  
 
These sequence differences suggest functional diversification of the paralogs. Indeed, 
these intrinsic differences in amino acid sequences result in varying signaling, 
interaction and modification motifs within each paralog. For instance, SUMO2/3 can 
be efficiently sumoylated at an internal lysine (K11), enabling the formation of 
polymeric SUMO2/3 chains on substrates (38). These SUMO2/3 chains have unique 
functional consequences, such as being recognized by the RNF4 SUMO targeted 
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ubiquitin ligase (STUbL) (39, 40). Through this PTM crosstalk, SUMO2/3 have the 
unique potential to target proteins for degradation through the ubiquitin-proteasome 
system. In fact, it has been hypothesized based on these STUbLs, that SUMO2/3 
conjugation and the ubiquitin-proteasome system are tightly integrated and interact in 
a cooperative manner (18). From an evolutionary standpoint, it is possible that the two 
pathways and interactions between them evolved as eukaryotes became more 
complex. This is in contrast to SUMO1, which is thought to be conjugated as a mono-
SUMO1 motif onto substrate lysine residues. However, SUMO1 has also recently 
been shown to act as a “cap” that terminates poly-SUMO2/3 chains (39, 41). 
Interestingly, these capped chains are not efficiently targeted for degradation by 
RNF4, but appear to be uniquely recognized and targeted for degradation by a STUbL 
called Arkadia/RNF111 (39). Thus, SUMO1, SUMO2/3 and mixed SUMO1-SUMO2/3 
chains are distinct signals with unique cellular consequences. 
 
In contrast to other SUMOs, SUMO4 possesses a proline residue in the C-terminus 
that may prevent processing by the SENPs, thus rending SUMO4 incapable of being 
activated and subsequently conjugated onto target proteins (42). It is therefore 
proposed that SUMO4 acts through non-covalent interactions with target proteins. 
However there is some confusion about this, given a subsequent study that found 
SUMO4 is conjugated to substrate proteins under conditions of stress, such as serum 
starvation (43). Consistent with this finding, approximately 90 SUMO4 substrates were 
identified, and many of them were chaperones and transcription factors involved in the 
regulation of cellular stress. Thus, two studies suggest that SUMO4 may function in 
cellular stress response pathways (44). Additionally, polymorphisms of the SUMO4 
gene have been linked to Type 2 diabetes in multiple ethnic groups, which is 
mechanistically attributed to the SUMO4 modification of IΚBα ultimately turning on NF-
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ΚB regulated genes (45). Collectively, more information is needed regarding the 
functional attributes and mechanisms of action associated with SUMO4. This includes 
a need for more data about when, or if, SUMO4 is conjugated onto target proteins.  
 
Lastly, there is only one biological function attributed to SUMO5, which involves 
regulating promyelocytic leukemia (PML) nuclear bodies (46). SUMO5 expression is 
highly tissue specific and limited to the testes and peripheral blood leukocytes (46). 
This suggests potential tissue-specific functions of SUMO5, though these have yet to 
be explored. Of note, SUMO5 is a predicted pseudogene of SUMO1, and as such, 
they differ by only 12 amino acid residues, many of which are located towards the N-
terminus. Collectively, more work is needed to assess the functional contributions of 
SUMO4 and SUMO5 to the SUMO pathway. As such, the remainder of this chapter 
will highlight the molecular attributes of the SUMO1-3 paralogs. Chapters 2 and 3 will 
then focus on a review of evidence for SUMO paralog-specific functions, and on our 
systematic discovery of non-redundant paralog-specific functions for SUMO1 and 
SUMO2. 
 
SUMO non-covalent interactions and PTM crosstalk 
 
Yet another similarity with ubiquitin is the ability of the SUMO paralogs to interact non-
covalently with target proteins that contain SUMO interacting motifs (SIMs) (47). SIMs 
in target proteins contain a hydrophobic core (for example, V/I-X-V/I-V/I) and are often 
flanked by acidic or serine residues (48, 49). As revealed by structural studies, the 
hydrophobic core of the target SIM interacts with a groove of SUMO formed by a β-
sheet and part of the α-helix (49-51). Interestingly, sequence differences between 
SUMO1 and SUMO2/3 are found in the second β-sheet and the α-helix, which 
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corresponds to the SIM interacting domains (52, 53). Functionally, charged lysine 
residues in this region are critical for the intrinsic ability of SUMO2 to function as a 
transcriptional repressor, as discussed in more detail in Chapter 2 (54). Moreover, 
SIMs have been identified in specialized SUMO E3 ligases, termed E4 elongases, 
which elongate SUMO2/3 chains (10, 55). One such E4, ZNF451, catalyzes chain 
formation through a tandem SIM region and has been associated with stress-induced 
SUMO2/3 conjugation (10).  
 
Lastly, the SUMO modifiers themselves can be regulated by other PTMs, such as 
phosphorylation (36), acetylation and ubiquitination (19), further adding to the 
complexity of the SUMO pathway and further highlighting the importance of its proper 
regulation. As explored in Chapters 2 and 3, understanding how the unique molecular 
attributes of the paralogs contribute to their specific functions will help us better 
understand why we have evolved to have multiple SUMO proteins.  
 
SUMO mechanisms of action 
 
The unique abilities of the individual SUMO paralogs to form chains or interact 
noncovalently with target proteins provides the SUMO pathway with a diversity of 
signals that regulate many essential processes. But what do these signals do to 
regulate such diverse and important cellular functions? Consistent with many PTMs, 
covalent or non-covalent modification by SUMO alters the overall surface and 
therefore the interaction domains of target proteins. This can have a wide range of 
effects, such as creating or blocking protein-protein interaction domains or creating 
competition with other PTMs for target lysine residues. This, in turn, can affect the 
localization, stability, activity and interacting partners of the target protein (Figure 4). 
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This is exemplified in nearly every SUMO interaction, with a few key examples 
highlighted here.  
 
First, SUMO-SIM interactions facilitate the formation of protein complexes, such as 
those used to mediate DNA double-strand break repair, regulate transcription and form 
nuclear bodies. For instance, once sumoylated, SIMs in the promyelocytic leukemia 
(PML) protein interact non-covalently with SUMO on itself and other SUMO-modified 
proteins, to form PML-nuclear bodies (PML-NBs) (9, 56-59). The SUMO-dependent 
formation of PML-NBs in turn regulates a variety of cellular functions, such as genome 
maintenance, telomere lengthening, the stress response, DNA repair, transcription, 
epigenetic modifications and the immune response (58-67).  
 
Secondly, sumoylation can block protein-protein interaction motifs. This is exemplified 
by SUMO modification of the Forkhead Box protein M1 preventing its homo-
dimerization and thus auto-repression, thereby increasing transcription (68). Cross-
talk between the ubiquitin and SUMO pathways through the recognition of poly-
SUMO2/3 chains by STUbLs, such as RNF4, can also target SUMO substrates for 
degradation. This is observed in DNA double-strand break repair, for instance, where 
SUMO and RNF4 are required for proper turnover of DNA repair factors (69). 
Conversely, sumoylation can also enhance the stability of target proteins through 
modification at shared ubiquitylation lysine motifs. This is exemplified by the SUMO-
mediated protection of Mdm2 and IΚBα, which are inhibitors of p53 and NF-ΚB, 
respectively. In the absence of SUMO modification, each of these proteins are instead 
ubiquitylated and consequently degraded by the proteosome (70, 71).  
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Lastly, sumoylation of proteins can directly alter their conformation, as is the case with 
thymine DNA glycosylase (TDG), an enzyme involved in nucleotide excision repair 
and DNA demethylation. Covalent and non-covalent modification of TDG by SUMO 
facilitates a conformational change that has been proposed to mediate release of TDG 
from DNA, thus allowing for subsequent factors to repair the DNA (72, 73). Of note, 
although structural studies support this model, an in vivo assay developed by our lab 
and collaborators found that sumoylation is not required for its enzymatic turnover, as 
SUMO conjugation and SUMO binding TDG mutants were equally able to mediate 
base-excision repair (74).  
 
In summary, there are a number of well-defined effects attributed to sumoylation, with 
specific consequences determined in large measure through context dependent 
effects on protein-protein interactions.  
 
The SUMO Pathway in Human Health and Disease 
 
 
Many SUMO-regulated processes, such as DNA repair, gene regulation and 
proteotoxic stress are misregulated in cancer, stroke, neurodegenerative diseases and 
heart disease. Thus, sumoylation is implicated in the development and progression of 
these non-communicable diseases that collectively kill tens of millions of people each 
year (64, 75-84). How can sumoylation be involved in so many various diseases? To 
begin, SUMO pathway components, such as the conjugating and deconjugating 
enzymes, are often misregulated. Since these enzymes are essential in maintaining 
the proper balance of SUMO modified versus un-modified target proteins, this 
misregulation can have dire consequences, as discussed below. Moreover, the 
proteins that are modified by SUMO are themselves critical in many disease-related 
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processes. Thus, similar to the multi-faceted nature of many diseases, the role 
sumoylation plays in them is also varied. In this section, I focus primarily on the role of 
sumoylation in human cancers, since that is most relevant to my work presented in 
Chapters 3 and 4. However, I also provide a broad overview of the role of sumoylation 
in neurodegenerative and inflammatory diseases. I conclude this section with a 
summary of current therapies targeting the SUMO pathway, followed by a brief 
perspective on the future of SUMO-targeting therapies.  
 
Sumoylation in Cancer 
 
The first direct link between sumoylation and cancer emerged with the discovery that 
sumoylation is essential for the successful treatment of patients who have Acute 
Promyelocytic Leukemia (APL) (85, 86). APL develops from a chromosomal 
translocation that occurs between the promyelocytic leukemia (PML) and retinoic acid 
receptor alpha (RARα) loci. The resulting oncogenic PML/RARα fusion protein is a 
potent repressor of nuclear hormone receptor signaling and also a disrupter of PML 
nuclear bodies (PML-NBs) (86). The functional consequence of this is repression of 
myeloid differentiation, which is a hallmark of leukemias (87, 88). APL is successfully 
treated with arsenic trioxide (As2O3), which mechanistically enhances the sumoylation 
of PML/RARα, specifically in the form of poly-SUMO2/3 chains. These chains are 
recognized by RNF4, which targets PML/RARα for proteasomal degradation (15, 85). 
Thus, treatment with As2O3 releases the differentiation block in APL by allowing PML 
and RARα to function normally, and leads to remission rates ranging from 72% up to 
92%, depending on the study (89). Therefore, despite being administered as a single 
agent, As2O3 is a potent therapy for treatment of APL, and its effectiveness is attributed 
in large part to SUMO. 
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Many cancers display changes in the sumoylation status of SUMO substrates that are 
involved in DNA repair, cell division and cellular signaling, which are also processes 
that are often misregulated in cancer. Changes in the sumoylation status are often 
attributed to altered levels of SUMO pathway enzymes, which are essential in 
regulating the proper balance of SUMO-modified versus unmodified protein targets 
(15). Changes in the sumoylation status of these target proteins directly impacts 
cancer-related processes, such as pro-survival signaling, inflammation and metastasis 
(76, 77). For instance, elevated levels of Ubc9, the sole SUMO E2 conjugating 
enzyme, results in enhanced tumor formation in breast, colon, lung, liver, prostate, and 
head and neck cancers (76, 90, 91). Ubc9 overexpression contributes to cancer 
progression by promoting migration and invasion of breast cancer cells, likely through 
enhanced sumoylation of proteins involved in these process, or through SUMO-
regulated changes in transcription (92). Consistently, elevated levels of Ubc9 are 
associated with more aggressive breast cancers and may be a predictor of 
chemoresistance (93). It is therefore unsurprising that elevated levels of Ubc9 are also 
associated with poor prognoses for many cancers in which it is overexpressed (76, 
93).  
 
Altered expression of the PIAS E3 ligases have also been reported in breast, gastric, 
ovarian, pancreatic, prostate and non-small cell lung cancers (14, 76). For instance, 
expression analysis of multiple PIAS genes has revealed downregulated expression 
of PIAS2 and PIAS3 in breast cancer tissues as compared to adjacent noncancerous 
tissues, but no change in PIAS1, and only a slight increase in PIAS4 (94). To dig 
deeper, the researchers stratified tumor types by hormone receptor expression, and 
found that PIAS1-3 had significantly decreased levels in estrogen receptor positive 
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(ER+) samples as compared to ER- negative samples, thus concluding that PIAS gene 
expression could determine responses to breast cancer antihormone therapies (94). 
Although a direct mechanism of action has not been proposed, through their activity 
as SUMO E3 ligases, PIAS proteins regulate the transcription of genes involved in 
cellular proliferation, differentiation and survival, thus their misregulation could be 
associated with pathogenesis (95). In line with this, the PIAS1 protein is overexpressed 
in human prostate cancer tissues and cell lines (96-98). PIAS1 facilitates sumoylation 
of the androgen receptor (AR), which is a critical regulator of prostate cancer 
pathogenesis (96, 99). Downregulation of PIAS1 leads to reduced cellular proliferation 
and colony formation, attributed to a G0/G1 cell cycle arrest (98, 99). Mechanistically, 
sumoylation of AR by SUMO1-3 has a negative effect on AR transactivation in prostate 
cancer cell lines (100). Thus, it is unclear how elevated levels of PIAS1, which 
presumably enhance the sumoylation of AR, are advantageous to prostate cancer 
cells. More work is needed to facilitate our understanding of AR regulation, but the 
many roles of PIAS proteins, including their regulation of JAK/STAT and other 
signaling pathways involved in prostate cancer, could be a driving force behind 
changes in PIAS1 levels in cancer cells (101, 102).  
 
Similar to the conjugating enzymes, misregulation of SENPs has also been implicated 
in the development and progression of multiple cancers (103-111). One well-studied 
SENP, SENP1, is overexpressed in multiple myeloma, neuroblastoma, prostate, 
thyroid and bladder cancers (76). In prostate cancer, SENP1 has been correlated with 
cancer aggressiveness and metastatic potential, and as such, can be used as a 
prognostic biomarker for this disease (34, 104, 109). Mechanistically, these findings 
are attributed partially to the induction of hypoxia-inducible factor 1 alpha (HIF1α) 
dependent signaling pathways (105). HIF1α is de-sumoylated by SENP1, which 
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increases its stability and transcriptional activity and thus promotes cancer cell survival 
(105). Of note, SENP1 regulation of HIF1α is described in more detail later in this 
chapter. Moreover, knockdown of endogenous SENP1 in prostate cancer cells inhibits 
cellular proliferation through desumoylation of the SMAD4 tumor repressor, which in 
turn promotes an epithelial to mesenchymal transition (EMT) driven by E-cadherin 
(104, 109). Thus, SENP1 regulates multiple critical cancer signaling pathways and its 
misregulation has important consequences. A study has also reported a correlation 
between increased levels of SENP1 and the development and progression of 
pancreatic ductal adenocarcinoma (112). This study formed the basis of my first thesis 
project and publication, which is presented in Chapter 4 (35).  
 
Other SENPs are also implicated in cancer. For instance, SENP3 is overexpressed in 
oral squamous cell carcinoma, colon and gastric cancers (76). Like SENP1, SENP3 
also regulates EMT. Mechanistically, SENP3 desumoylates the Forkhead box protein 
C2 transcription factor, which induces expression of EMT- promoting genes in gastric 
cancer cells (113). On the other hand, SENP2 is downregulated in cancers such as 
bladder, liver, osteosarcoma and chronic lymphocytic leukemia (CLL) (106, 114, 115). 
The low expression levels observed across various cancer types suggests that SENP2 
is a tumor suppressor. Consistent with this suggestion, SENP2 negatively regulates 
cellular proliferation and migration in both CLL and osteosarcoma through regulation 
of β-catenin and SOX9 transcription factor stability, respectively (114, 115). 
Intriguingly, our lab has identified interactions between SENP2 and cytoplasmic 
membranes (29). Whether control of sumoylation at membranes is associated with 
pathogenesis is unknown but could be interesting to explore.  
 
 31 
Collectively, although there is a trend towards SUMO pathway enzyme up-regulation 
in numerous cancers, decreased expression of PIAS in breast cancer tissues and 
SENP2 in various cancer cell lines demonstrate that this is not always the case. This 
suggests that in certain cellular contexts, SUMO regulators may either contribute to or 
inhibit pathogenesis. What is consistent, however, is the loss of properly balanced 
sumoylation in each of these contexts. Balanced sumoylation is essential for 
maintaining cellular homeostasis, as revealed by the numerous cancers associated 
with misregulated sumoylation, and the requirement of properly regulated sumoylation 
in many organisms, as discussed in Chapter 2 (111, 116). Moreover, since many 
SUMO targets are critical regulators of cancer-related processes, as discussed in the 
following section, misregulation of the SUMO pathway components has serious 
implications for cancer development and progression (76, 111).  
 
SUMO regulation of tumor suppressors and oncogenes 
 
 
The protein product of the breast and ovarian cancer susceptibility gene, BRCA1, is a 
RING finger E3 ubiquitin ligase, and also a SUMO substrate and SUMO binding 
protein (117, 118). BRCA1 functions as a tumor suppressor through mediating 
accurate DNA repair, which is critical in preventing the initiation of many cancers (119). 
As such, mutations in the BRCA1 RING domain are associated with increased risk of 
breast and ovarian cancer. Our lab has shown that RAP80, a protein that is required 
for stabilizing BRCA1 at sites of DNA double-strand breaks, recruits BRCA1 to these 
sites through non-covalent binding of RNF4 catalyzed hybrid SUMO-ubiquitin chains 
(118). Moreover, sumoylation also enhances the interaction of BRCA1 with a ubiquitin 
E2 conjugating enzyme at sites of DNA repair, subsequently enhancing its activity as 
an E3 ligase (76, 117). Mutations in the BRCA1 RING domain lead to the loss of 
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ubiquitin E3 ligase activity and SUMO-mediated localization of BRCA1 to sites of DNA 
damage. Thus, although the role of SUMO in regulating mutated and pathogenic 
BRCA1 is not fully understood, the fact that SUMO-regulated BRCA1 activity and 
localization are lost in the mutant protein suggests that sumoylation may be relevant 
in the development, progression and perhaps treatment of cancers with BRCA1 
mutations (117).  
 
The Ras and Myc oncogenes are frequently misregulated in pancreatic, lung, colon 
and breast cancers, and are also involved in driving their progression (120). 
Intriguingly, genome-wide shRNA screens have identified the SUMO activating and 
conjugating enzymes as synthetic lethal partners for both of these oncogenes, as 
discussed below, further highlighting the importance of the SUMO pathway in human 
cancers (15).  
 
The Ras family of small GTPases are signal transducing molecules that act 
downstream of growth factor receptors and regulate essential processes such as 
cellular proliferation and motility. Activating mutations in Ras family proteins, namely 
KRAS, are found in many aggressive cancers and unfortunately for patients, have 
evaded successful targeting with chemotherapeutic agents (121). In an effort to 
identify other targets that effect KRAS-driven cancers, and might ideally be easier to 
target therapeutically, a synthetic lethal shRNA screen was performed in two 
independent human colorectal cancer cell lines. From this screen, the SUMO 
activating and conjugating enzymes, SAE1, UBA2 and Ubc9, were all identified as 
synthetic lethal partners with KRAS (122). It was subsequently found that the SUMO 
pathway, notably Ubc9, is required for KRAS driven transformative growth of colon 
cancer in mice and in vitro assays (123).  
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Of relevance to Chapters 2 and 3 of this thesis, the authors of the KRAS study directly 
explored the contributions of the individual SUMO1, SUMO2 and SUMO3 paralogs on 
the colony formation ability of KRAS mutant cancer cells and found intriguing 
differences. For instance, depletion of SUMO1 only modestly decreased the viability 
of KRAS mutant cells and had little effect on colony formation size. In contrast, co-
depletion of SUMO2/3 (targeted by individual SUMO2 and SUMO3 shRNAs) 
significantly reduced the colony formation ability of KRAS mutant cells as compared 
to WT, though they also only slightly effected viability. Moreover, the authors also 
looked at anchorage independent growth, which is a method used to assess the 
metastatic potential of cancer cells, and again found unique and non-redundant 
paralog-specific functions (124). Specifically, they demonstrated that loss of SUMO1, 
SUMO2, SUMO2+SUMO3 and SUMO1+SUMO2+SUMO3 each significantly reduced 
anchorage independent colony formation, but loss of SUMO3 alone did not have a 
significant effect. This suggests non-redundant roles for SUMO1 and SUMO2, but not 
SUMO3, in this process. Interestingly, when rescue experiments were performed, re-
expression of SUMO1 rescued SUMO1 colony number and size phenotypes but was 
unable to rescue SUMO2 phenotypes. Consistently, only the SUMO2 phenotypes 
were rescued upon SUMO2 re-expression. Taken together, these findings reveal that 
the SUMO1 and SUMO2 paralogs play functionally distinct roles in the colony 
formation ability of KRAS mutant cells, with SUMO2 appearing to have a broader role 
in clonogenic growth (123).  
 
A similar screen was used to identify UBA2, a subunit of the SUMO E1 activating 
enzyme, as a synthetic lethal partner in Myc-driven tumors in human mammary 
epithelial cells (125). Mechanistically, they found that loss of UBA2 leads to mitotic 
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defects, likely through the mis-regulated sumoylation of proteins involved in mitosis, 
as further discussed in the next chapter. Lastly, they also found that low levels of the 
E1 in breast cancer tumors correlated with longer metastasis-free patient survival, 
again highlighting the importance of sumoylation in cancer progression and as a 
potential therapeutic target, as discussed at the end of this chapter (15, 125).     
 
Sumoylation in Neurodegenerative Disease 
 
A common feature of neurodegenerative diseases is the accumulation of misfolded 
and aggregated cellular proteins. Individual neurodegenerative diseases are identified 
and classified by the proteins found in these aggregates, and the localization of the 
aggregates. For instance, the huntingtin protein is observed in nuclear aggregates in 
Huntingtin’s disease, and amyloid-β is found in deposits in the brain of patients with 
Alzheimer’s disease (81, 126). The SUMO paralogs localize to these deposits and 
aggregates, and many neurogenerative disease-associated proteins are sumoylated. 
Thus sumoylation is clearly linked to neurodegenerative diseases (78, 81, 127). For 
instance, the mutated huntingtin protein (Htt) can be modified by both SUMO1 and 
SUMO2 in vitro (84, 128). Moreover, conjugation of SUMO1 to the same lysine 
targeted by ubiquitylation increases the abundance, stability and toxicity of mutant Htt 
in an in vivo Drosophila model and in cell culture (126). Consequently, decreased 
levels of SUMO1 modification are predicted to have a protective role in Huntington’s 
disease (126).   
 
Moreover, SUMO2/3 regulates the degradation of misfolded ataxin-7 (polyQ-ATXN7), 
which is the hallmark protein of a neurodegenerative disorder called spinocerebellar 
ataxia type 7 (SCA7) (127, 129). PolyQ-ATXN7 aggregates form intranuclear neuronal 
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inclusions, which contain transcriptional regulators, proteasome subunits, PML, 
ubiquitin and SUMO (126, 129). Mechanistically, in vivo and in vitro experiments 
suggest that misfolded polyQ-ATXN7 is specifically recognized and modified by poly-
SUMO2/3 chains. These chains are recognized by the STUbL, RNF4, which targets 
the mutant protein for degradation. It has been suggested that as neurons age and the 
proteasome becomes less active, degradation is compromised, leading to the 
formation of nuclear aggregates in SCA7 patients (129). Possible age-related declines 
in sumoylation may also contribute to disease progression. In summary, there is more 
work to be done to study the roles of sumoylation in neurodegenerative diseases, but 
the evidence thus far suggests it would be a worthwhile effort. 
 
Sumoylation in Inflammatory Disease 
 
In addition to cancer and neurodegenerative diseases, sumoylation is also involved in 
inflammatory and autoimmune diseases. This is due to SUMO regulation of Type I 
interferons (IFNs), which are produced upon detection of viral nucleic acids (130). 
Despite the essential role of IFNs in defending the host from viral infection, IFNs are 
also misregulated in many inflammatory and autoimmune disorders, such as Systemic 
Lupus Erythematosus (131). SUMO-regulated IFN responses have been observed at 
the levels of global sumoylation and at the paralog-specific level, as described below.  
 
First, using differentiated bone marrow cells derived from Ubc9-/- conditional knockout 
mice, an increase in pro-inflammatory mediators were observed as compared to cells 
from Ubc9+/+ mice. Moreover, the Ubc9-/- cells stimulated with lipopolysaccharide, 
tumor-necrosis factor and other pattern-recognition receptor agonists had exacerbated 
inflammatory responses. To demonstrate that this was not cell-type specific, the 
 36 
authors also confirmed these findings in Ubc9-/- cells derived from bacteria infected 
mouse embryonic fibroblasts, and in a human monocyte cell line. Taken together, 
these findings reveal that sumoylation has as critical role in negatively regulating 
inflammation in vivo. Mechanistically, it was found that sumoylation silenced the 
normally constitutive expression of the gene encoding IFN-β, and restrained the 
activation of Ifnb by Toll-like receptor ligands (130). A second group looked more 
closely at the individual roles of the SUMO paralogs in regulating the inflammatory 
response. Using human monocytes, they found that loss of SUMO2 and SUMO3 
together resulted in a significant increase in IFNs, and thereby a subsequent increase 
in IFN-stimulated genes. Thus, this work specifically demonstrated that SUMO2 and 
SUMO3 are essential negative regulators of inflammation. Of note, using targeted 
lysine mutations (K11R and 5KR), it was found that the poly-SUMO2/3 chain forming 
abilities of SUMO2 and SUMO3 were not required for this response. Moreover, the 
authors sought to identify the pathways responsible for triggering this IFN response in 
SUMO2/3-deficient cells through looking at canonical IFN-inducing pathways and 
transcription factors, such as nucleic acid sensing and metabolism pathways (STING 
and MAVS), the TBK1-related kinases, and IRF3 and IRF7 transcription factors. 
Interestingly, the IFN response caused by loss of SUMO2/3 is independent of all 
canonical IFN-inducing pathways, suggesting a distinct mechanism of IFN regulation. 
One possibility the authors suggest is that alternative transcription factors besides 
IRF3 and IRF7 are regulated by SUMO2/3, and in SUMO deficient cells, they trigger 
an IFN response (132). Consistent with these findings, we also identified many up-
regulated IFN-related genes upon knockout of SUMO2 in U2OS cells, as discussed in 
Chapter 3.  
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Lastly, and further consistent with the role of sumoylation in the Type I IFN response, 
sumoylation also regulates host viral responses (133). For instance, upon infection 
with influenza, host proteins involved in transcription, mRNA processing, RNA quality 
control and DNA damage repair become sumoylated (134). Thus, sumoylation is an 
important regulator of viral responses and the immune system, and its misregulation 
could have important consequences. 
 
Sumoylation in Chronic Mountain Sickness 
 
Interestingly, there are multiple single nucleotide polymorphisms (SNPs) in the SENP1 
gene that are associated with susceptibility to chronic mountain sickness (CMS) in 
Andean highlanders (15, 135-138). The first SNP reported, rs7963934, is located in 
intron 6 and involves a cytosine to a guanine (C/G) change (137) (Figure 5). This SNP 
has been identified as being protective against CMS patients from the Peruvian Andes 
(135). 
 
A subsequent study identified 66 differential SNPs between CMS and non-CMS 
individuals, and found that cells from CMS individuals had increased expression of 
SENP1 at both the gene and protein levels when grown under hypoxic conditions (137, 
138). Of note, when grown under hypoxic conditions, the CMS patient-derived cells 
had an approximate 60% increase in CD235a, an erythroid marker used as a proxy 
for red blood cell levels, as compared to cell lines derived from non-CMS and sea-
level residing individuals. Moreover, when SENP1 expression was depleted by 
shRNAs in these same cell lines, the proportion of CD235a fell to <1% of the level of 
CMS cells. Consistently, SENP1 overexpression in the non-CMS cell lines increased 
the proportion of CD235a to 40% more than non-CMS derived cells. Taken together, 
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these findings suggest that SENP1 may play a functional role in the observed increase 
in red blood cells that occurs in CMS patients (138).  
 
A possible, and likely, molecular explanation for the association of SENP1 SNPs and 
CMS is based on the regulation of HIF1α by SENP1. Under normoxic conditions, 
HIF1α is localized in the cytoplasm, where it is hydroxylated and subsequently 
degraded by ubiquitin. Under hypoxic conditions, HIF1α is no longer hydroxylated and 
localizes to the nucleus, where it is sumoylated. SUMOylated HIF1α is subsequently 
targeted for degradation by ubiquitin, unless SENP1 stabilizes the transcription factor 
by removing SUMO. Desumoylated HIF1α dimerizes and turns on hypoxic genes such 
as erythropoietin (Epo), glucose transporter (Glut-1) and vascular endothelial growth 
factor (VEGF) (15, 105). Taken together, SNPs in SENP1 are associated with CMS, 
and likely contribute to an up-regulation of SENP1 in CMS patients. Given that this 
association has been shown by multiple independent groups using in vivo (cell culture) 
assays and rigorous bioinformatic analyses, it could be worth exploring as a 
therapeutic target.  
 
Sumoylation as a Therapeutic Target 
 
Collectively, the involvement of sumoylation in diseases ranging from cancer to viral 
infection have led to the emergence of the SUMO pathway as an attractive therapeutic 
target (76, 139). As such, there is currently a SUMO E1 inhibitor, TAK-981, that is in 
four concurrent Phase I clinical trials, all for the treatment of various human cancers 
(140-143). Timely, the most recently initiated trial is recruiting cancer patients who 
have also tested positive for COVID-19, a viral infection caused by the novel SARS-
CoV-2 coronavirus that has caused a global pandemic, which we are currently still 
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living through (144). While we hope TAK-981 will be successful in treating cancer 
patients and possibly COVID-19, it is likely that there will be cytotoxic effects due to 
inhibiting the conjugation of all SUMO paralogs. Therefore, it might be prudent to 
develop a more selective SUMO paralog inhibitor, for instance, one that only targets 
SUMO2/3 if the goal is to increase the IFN response. At a molecular level, this could 
be achieved through designing a drug that targets the SIM interaction domain of 
SUMO2/3, since it is distinct from that of SUMO1 (49). Moreover, SIM interacting 
domain synthetic peptides (Affimers) and “monobodies” have already been developed 
and are used in the lab, thus providing viable proof of concept designs (49, 145).  
 
Beyond targeting the SUMO paralogs, it could also prove advantageous to selectively 
target the SUMO E3 ligases and deconjugating enzymes that display paralog 
specificity (20, 76). For instance, it has been suggested that E3 ligases may be 
effective targets for neurodegenerative diseases, however there are currently no 
PIAS-inducing therapies in the clinic (126). As such, designing viral vectors that 
selectively target the brain where they can express PIAS proteins could be a potentially 
efficacious strategy, especially to increase the SUMO2/3 modification of mutated 
ATXN7. Interestingly, since IFN-β upregulates both PML and SUMO2/3 conjugated 
proteins, it could also be a viable therapeutic agent for proteasomal degradation of 
mutant ATXN7 (129). Moreover, as SENP1 is upregulated in many human cancers, 
researchers have started developing targeted inhibitors. Although they have shown 
success killing prostate cancer cells in the lab, optimization is needed before going 
into patients (146). In summary, through studying the basic biology of sumoylation and 
enhancing our understanding about its contributions to misregulated processes driving 
numerous diseases, we are meeting the vision of the Johns Hopkins Bloomberg 
School of Public Health: Protecting Health, Saving Lives - Millions at a time.   
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Overview of Thesis Work 
 
 
The work described in this thesis centers on the SUMO pathway, starting with a focus 
on the unique roles of the paralogs, and ending with the use of a SUMO specific 
isopeptidase as a biomarker for cancer therapy. Chapter 2 highlights evidence from 
the literature for SUMO paralog specific functions. These paralog specific functions 
are further explored and described in Chapter 3, where we use CRISPR-Cas9 to knock 
out SUMO1 and SUMO2 from human cancer cells in order to systematically evaluate 
the cells for non-redundant paralog functions. Our findings provide evidence for unique 
and non-redundant paralog-specific roles. More specifically, we identify unique roles 
for the paralogs in regulating cellular morphology, nuclear body formation, gene 
expression and in the cellular stress response. Collectively, our data reveal that loss 
of SUMO2 has a more robust effect on biological function than loss of SUMO1, though 
loss of SUMO1 is not without consequence. This suggests that therapeutically 
targeting the paralogs more precisely could be an advantageous strategy as compared 
to non-specific targeting of all five SUMO paralogs.  
 
We then develop a workflow for identifying the most optimal cancer patients for 
treatment with a SUMO inhibitor, as discussed in Chapter 4. Since misregulated SENP 
levels in human cancers are often reported, we used SENP1 expression as a proxy 
for total SUMO levels. Consistent with the literature, we found that elevated levels of 
SENP1 indeed lead to a corresponding decrease in levels of SUMO conjugated 
proteins (76), and thus hypothesize that patients with elevated levels of SENP1 might 
be more sensitive to treatment with a SUMO inhibitor. Although we are still in the 
process of testing this hypothesis, we were able to successfully develop an easy to 
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use workflow for accessing the utility of an annotated protein as a biomarker for 
common human cancers. We used this workflow to evaluate SENP1 gene and protein 
expression in pancreatic cancer cell lines and human tissues. This disease was 
selected based on a previous report that SENP1 was overexpressed in pancreatic 
cancer. However, we used validated cell lines and robust bioinformatics resources and 
concluded that SENP1 is not overexpressed and thus not likely to be an effective 
biomarker for pancreatic cancer. Our aim is that, in future studies, this workflow can 
be used to identify human cancers where the SUMO pathway is mis-regulated, thus 
providing predictive biomarkers for treatment of cancers with a SUMO inhibitor. Taken 
together, this work highlights the importance of the SUMO pathway, from the paralogs, 
to the SUMO pathway enzymes, in human health and disease, and opens many doors 







Figure 1. Overview of the SUMO pathway and paralog homologies. A) Small ubiquitin 
related modifiers (SUMOs) are covalently attached to substrate proteins through an E1, E2, E3 
enzymatic cascade. This modification is reversible through the catalytic activity of SUMO 
proteases, called SENPs. B) The five human SUMO paralogs, SUMO1-5, have varying amino 
acid homologies. In this figure, the SUMO2-5 amino acid sequences are compared to SUMO1, 
where the dark lines represent a non-conserved amino acid residue. As shown, SUMO2/3/4 
are approximately 97% identical, whereas SUMO1 only shares ~45% homology with 




Figure 2. Genomic Location of SUMO Pathway Components. The SUMO paralogs 









Figure 3. SUMO Protease Schematics. Humans have six SUMO proteases (SENPs). 
SENP1-3 and SENP5 have conserved catalytic domains (orange). The SENPs have divergent 
N-termini that contain unique targeting signals (green), such as nuclear localization signals, 
nuclear pore complex interaction domains, SUMO interacting motifs and phosphorylation sites.  
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Figure 4. Substrate modification by SUMO has diverse effects. SUMO conjugation onto a 
target substrate protein, as shown in the center, can have a variety of biological effects. A) 
SUMO modification can form new protein interaction domains. B) Conversely, SUMO 
modification can block, or inhibit protein interaction domains. This can be sterically, or through 
blocking other PTMs that modify lysine residues, such as ubiquitin (Ub). C) SUMO modification 
can activate a target protein. D) SUMO modification can facilitate non-covalent interactions 
with proteins that contain a SUMO Interacting Motif (SIM), or E) many SIMs. This can have 
stabilizing, or degradation effects. F) Modification by poly-SUMOs allow for cross-talk between 
the SUMO and ubiquitin pathways, mediated by SUMO targeted ubiquitin ligases (STUbLs), 







Figure 5. A SENP1 SNP in Chronic Mountain Sickness. Views of a SNP in the SENP1 gene 
that are associated with chronic mountain sickness. A) A view of the SENP1 gene, showing 
the location of SNP RS7963934 in Intron 6, as marked by a magenta line. B) A zoomed-in view 
of the SNP, showing its location in Intron 6, but near Exon 7, again marked with a magenta 
line. C) A nucleotide view of the SNP, showing a cytosine in the reference sequence 










Chapter 2: The Unknown Knowns of Sumoylation – 








Previous explorations of the SUMO pathway in yeast, mice and human cells have 
revealed conserved functions for sumoylation in chromosome segregation, nuclear 
architecture, development, the cellular stress response and transcription. These 
findings have revealed varying requirements for the SUMO paralogs in diverse 
biological processes, indicating that the paralogs have unique and non-redundant 
cellular functions. Although a handful of studies have directly examined paralog-
specific functions, many fundamental questions still remain about why multiple SUMO 
paralogs have evolved and what their unique functions are. To better position 
ourselves to answer these questions, we turned to the literature to uncover the 
unknown knowns of the SUMO paralogs. More specifically, we looked for evidence of 
SUMO paralog specific functions in diverse model systems and in various biological 
processes. This chapter starts with an overview of what we know about SUMO 
modifiers in commonly studied model organisms, revealing a requirement for 
sumoylation in these systems. We then highlight studies that have explored the SUMO 
paralogs using cell culture conditions and in vitro assays. From studies in these 
systems, we report evidence for paralog-specific roles in the stress response, DNA 
repair, nuclear body integrity, mitosis and transcription. These roles are mediated 
through paralog-specific modification of unique substrate proteins. The functional 
outcomes of modification by different SUMO paralogs are complex but center around 
varying effects on protein-protein interactions and protein stability. Our experimental 
approach to enhancing our understanding of paralog-specific biological functions is 





Evidence from Non-Human Model Organisms 
 
 
Although the work in this thesis focuses on human SUMOs, much of what we know 
about these modifiers has come from studies in non-human organisms. Thus, it is 
important to highlight some of the molecular functions and features of the SUMO 
modifiers from commonly studied eukaryotic species, as summarized in Figure 6. 
 
Yeast have a single SUMO, called Smt3. Human SUMO1-3 paralogs each share 
approximately 50% sequence identity with Smt3 (147). In Saccharomyces cerevisiae, 
mutations in the Smt3 gene, or in the E1 or E2 activating and conjugating enzyme 
genes, leads to non-viable yeast. These mutants arrest at the G2/M phase of the cell 
cycle, highlighting the importance of sumoylation for viability and in cell cycle 
regulation (148). Moreover, a systematic analysis of Smt3 mutants performed by our 
lab noted that some mutations in the Smt3 SIM-binding surface were lethal, thus 
revealing the critical importance of non-covalent SUMO-SIM interactions in organism 
survival (147). Lastly, similar to human SUMO2/3, Smt3 can also form chains. While 
Smt3 chain formation is not required for viability, it does enhance the response to 
numerous stress conditions (147). Of note, invertebrates such as Drosophila and 
Caenorhabditis elegans each have one gene coding for a single SUMO paralog 
(Figure 6) (149). In C. elegans, SUMO is called smo-1 and its deletion is lethal (150). 
 
Interestingly, the Arabidopsis thaliana plant has eight SUMO paralogs (AtSUMO1-8), 
though only four (AtSUMO1,2,3 and 5) appear to be functional PTMs (148, 151). In 
contrast to the human paralogs, AtSUMO1 and AtSUMO2 are the most closely related, 
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sharing 89% homology, whereas AtSUMO2 and AtSUMO3 only share 48% homology 
(152). Moreover, AtSUMO1 and AtSUMO2 have internal consensus site lysine 
residues that allow for efficient chain formation, analogous to human SUMO2/3. In 
contrast, AtSUMO3 lacks this internal modification site, which is similar to human 
SUMO1 (153). Interestingly, although AtSUMO1 and AtSUMO2 are the most closely 
related, co-deletion of both paralogs results in plant death. However, single deletions 
of AtSUMO1 or AtSUMO2 has no effect on plant development, thus revealing 
redundant functions of AtSUMO1 and AtSUMO2 in this critical process (151, 153). 
Lastly, it is proposed that the AtSUMOs are more functionally divergent than their 
human orthologues (152). This is based on findings that non-conserved residues on 
the surface of AtSUMO3 and AtSUMO5 are less efficiently recognized by the A. 
thaliana E1 activating enzyme (AtE1) and are also deficient at forming non-covalent 
interactions with the AtE2 conjugating enzyme. This results in AtSUMO3 and 
AtSUMO5 being less efficiently conjugated to other proteins compared to AtSUMO1 
and AtSUMO2. The overall consequence of this is that AtSUMO1 and AtSUMO2 are 
evolving to be the preferred SUMO paralogs (152).  
 
Consistent with the requirement of sumoylation for viability in yeast, worms and plants, 
sumoylation is also essential for mouse embryogenesis (63). This essential function 
was first demonstrated by the inability to generate mice upon deletion of the single E2 
conjugating enzyme, Ubc9. A closer examination of the developmental timeline of 
Ubc9-/- mice found that the embryos successfully develop to the blastocyst stage and 
undergo uterine implantation, but then die before embryonic day 7.5, presumably as 
cellular pools of maternal Ubc9 are depleted (63). Thus, sumoylation is essential in 
the post-implantation phase of development. What about paralog-specific roles in this 
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process? Similar to humans, mice have four SUMO paralogs (SUMO1-4), of which, 
the contributions of SUMO1-3 have been studied in mouse development (46, 154).  
 
One study in mice aimed to better understand the distinct functional roles of the highly 
homologous SUMO2 and SUMO3 paralogs, since they only differ by three amino 
acids. Analysis of SUMO2 and SUMO3 null mice revealed that SUMO2 is essential for 
embryonic development whereas SUMO3 is not (155). Closer examination of the 
SUMO2 null mice found that they died around embryonic day 10.5. In contrast, 
SUMO3 null mice were recovered in expected Mendelian ratios, were fertile and 
lacked any overt phenotypic abnormalities. Analysis of total SUMO1-3 mRNA levels 
from embryonic day 7.5 and 8.5 mice revealed that SUMO2 accounted for >70% of 
total SUMO mRNA, in contrast to SUMO3, which only accounted for ~3%. The 
remaining approximately 20% was from SUMO1. It was thus proposed and later 
revealed that the overall loss of total SUMO in the SUMO2 KO mice resulted in 
embryonic death, which was due specifically to the loss of the predominant SUMO2 
isoform. Unfortunately, the authors did not try to rescue the SUMO2 embryonic lethal 
phenotype with overexpression of SUMO3, thus it remains unclear whether elevated 
levels of SUMO3 would functionally compensate for SUMO2. Interestingly, the authors 
also looked at SUMO1 and SUMO3 mRNA levels across adult wildtype mice and found 
that SUMO3 levels increase to almost 20% of total SUMO mRNA across multiple 
tissues, suggesting that SUMO3 may have unique and relevant biological functions 
post-development (155). Taken together, loss of SUMO2 is embryonic lethal and is 
not compensated for by SUMO1 or SUMO3. Whether the essential requirement for 
SUMO2 is due to functionally distinct properties, or due to its elevated gene expression 
levels, remains to be investigated (155). 
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While loss of SUMO2 is detrimental in mice, and loss of SUMO3 does not appear to 
have any developmental or phenotypic defects, the story is significantly less clear with 
regard to loss of SUMO1. The confusion began in 2006 when a 5 year old girl with 
cleft-lip and palate was found to have a mutation in the SUMO1 gene that led to 
decreased SUMO1 mRNA and protein levels in patient samples. Given that 
sumoylation regulates many developmentally important proteins, an association was 
made between the loss of SUMO1 and the orofacial defect (156). To further study this 
finding in vivo, SUMO1 mutant mice were bred using embryonic stem cells, and a 
small fraction of heterozygous mutant mice were reported to have orofacial defects 
(157). However, a subsequent study using unspecified mice strains, but bred using 2 
different embryonic stem cells (one of which was from the original paper), were unable 
to replicate these findings. In fact, they found that both strains of the SUMO1 null mice 
were produced at expected Mendelian ratios and were phenotypically normal. Thus, 
they came to the conclusion that SUMO1 is not required for development, nor for 
proper orofacial development, owing to functional compensation by the other SUMO 
paralogs. Of note, they suggested that previously reported phenotypic observations 
may have resulted from an off-target effect (158).  
 
The finding that SUMO1 is dispensable for mouse embryonic development was 
supported by a second independent research group that generated SUMO1 knockout 
(KO) mice using a well-documented and conventional KO of the SUMO1 locus 
following homologous recombination. They found that these mice developed normally 
and did not have any overt phenotypes, and again concluded that SUMO1 is 
dispensable for development (159). However, a subsequent study from this same 
group found that adult SUMO1 KO mice fed a high fat diet gained less weight and had 
smaller and fewer adipocytes than WT littermates. Mechanistically, they found that 
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SUMO1 regulates adipogenesis through affecting the transcriptional activity of a 
nuclear receptor that mediates insulin sensitivity (160). Further adding to the 
complexity surrounding the role of SUMO1 function, a final independent research 
group studied two previously tested strains of SUMO KO mice, and although they did 
not observe orofacial defects, they did find congenital heart defects in both strains 
(79). Taken together, the findings reveal that although loss of SUMO1 is not embryonic 
lethal, it is not without consequence. While the precise consequences require further 
exploration, it is likely that the context, such as mice strains and knockout method, 
have important confounding effects. A final note about cleft palate, SUMO1 does not 
appear to be implicated in this orofacial defect, as an independent research group 
genotyped and performed haplotype association studies on over 400 Central-
European controls and patients with cleft-palate, and found that none of the analyzed 
SUMO1 single nucleotide polymorphisms had significant associations with the defect 
(161).  
 
In summary, studies in non-human model organisms have revealed regulatory roles 
for sumoylation in development, cell cycle, the stress response and transcription. In 
organisms with a single SUMO paralog, loss of this modifier is lethal. In organisms 
with multiple paralogs, there appears to be a minimal level of total SUMO expression 
that is required for viability, and possible critical functions for individual paralogs. 
Taken together, this indicates that sumoylation is an essential PTM for many 





Evidence from Human Cell Culture and In Vitro Experiments 
 
 
Consistent with findings from other eukaryotes, studying the regulatory roles of 
sumoylation in cultured human cell lines has also revealed important functions. For 
instance, sumoylation is involved in chromosome dynamics, gene regulation, DNA 
repair, recombination, nuclear import, nuclear body integrity, the cellular stress 
response and the immune response (66, 76, 78, 134, 162-165). Despite this 
knowledge, what we know about the contributions of the individual paralogs to these 
important biological processes is less clear. This section therefore highlights studies 
that have taken into consideration the unique attributes of the SUMO paralogs in 
human cell lines and using in vitro assays. Specifically, this section includes studies 
that evaluated paralog specific preferences of various SUMO pathway enzymes and 
target proteins, and that explored the functions of the SUMO paralogs in various 
biological processes. This section has a particular emphasis on paralog-specific 
functions in transcription, because of the high percentage of SUMO substrates that 
are transcription factors and chromatin remodeling proteins, and also because of my 
contributions to the work presented in Chapter 3, which focuses heavily on the unique 
roles of SUMO1 and SUMO2 in gene expression. This section concludes with a 
discussion highlighting some caveats of past methodologies, and how these methods 
have potentially confounded our understanding of the unique roles of the SUMO 
paralogs. Collectively, this section highlights the background, significance and impact 
of our work systematically identifying non-redundant paralog specific functions 




Paralog-Specific Preferences of the SUMO Pathway Enzymes 
 
The SUMO conjugation and deconjugation enzymes display paralog-specific 
preferences, thus providing a mechanism for paralog-specific regulation of target 
proteins. For instance, the PIAS1 E3 ligase has a preference for enhancing the 
conjugation of SUMO2 onto target proteins, whereas the RanBP2 E3 ligase has a 
preference for SUMO1 (10). RanBP2 in particular enhances the transfer of SUMO1 
from Ubc9 to target proteins such as SP100 and HDAC4 (166, 167). Furthermore, 
RanGAP1, a nuclear pore complex protein, is selectively modified by SUMO1 in vivo 
(6). This paralog specificity is achieved through a protective high affinity interaction of 
SUMO1 with RanBP2, which selectively protects SUMO1 from being cleaved by 
isopeptidases (168). Lastly, an E4 elongase, ZNF451, has a preference for SUMO2/3. 
This preference is attributed to dual SIMs in ZNF451 which interact with the N-terminus 
and SIM interaction surface of SUMO2/3 (10). In each of these examples, paralog-
specific SUMO-SIM interactions appear to underlie specificity. 
 
SUMO proteases also demonstrate paralog-specific preferences. For instance, 
although SENP1 and SENP2 can each de-conjugate SUMO1-3 from substrate 
proteins in vitro, SENP1 is more efficient at proteolytically processing SUMO1 into its 
active form. This is dictated by differences in electrostatic surface interactions of the 
different paralogs with SENP1 (169). Moreover, despite general conservation among 
the C-terminal catalytic domains of individual SENPs (Figure 3), SENP6 and SENP7 
have the most divergent catalytic domains, which partially dictate their preferences for 
deconjugating SUMO2/3 from target substrates (20). This selectivity is guided by the 
interaction of a C-terminal loop in SENP6/7 with two polar residues that are found 
uniquely on the surface of SUMO2/3 (N68 and D71). When the analogous residues 
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are swapped between SUMO2/3 and SUMO1, SENP6 and SENP7 then display a 
preference for SUMO1 over SUMO2/3 (170).  
 
Taken together, differences in the SUMO surfaces directly contribute to paralog 
specificity regulated by SUMO conjugating and deconjugating enzymes. Moreover, 
the finding that SUMO pathway enzymes have preferences for the paralogs provides 
support for the hypothesis that the paralogs act as distinct cellular signals that can be 
individually regulated.  
 
Paralog-Specific Modification of SUMO Substrates 
 
Proteomics and cell-based assays have demonstrated that SUMO1 and SUMO2/3 can 
be conjugated to unique proteins (19, 171-174). For instance, an early mass 
spectrometry (MS) study using tagged SUMO1 and SUMO3 identified 122 novel 
SUMO substrates. Consistent with known SUMO-regulated functions, many of these 
proteins were transcription factors, nucleic acid binding proteins and cellular structural 
components. Relevant to SUMO paralogs having distinct functions, only 27 of these 
proteins were modified by both SUMO1 and SUMO3, and nearly twice the number of 
SUMO1 substrates were identified as SUMO3 (171). Two other independent MS 
studies also found that 40-50% of identified proteins were uniquely modified by 
SUMO1 compared to approximately 10% that were uniquely modified by SUMO2 (172, 
173). Recent proteomics studies have focused on the identification of SUMO2/3 
substrates under conditions of stress, as opposed to identifying unique SUMO1 and 
SUMO2/3 modified substrates (175-177). Moreover, a 2016 comprehensive analysis 
of all SUMO proteomics studies combined SUMO1 and SUMO2/3 datasets together, 
thereby identifying thousands of sumoylated proteins and sumoylation sites, but 
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unfortunately not revealing unique insights about paralog-specific target proteins (19). 
Thus, although new proteomics technologies are being developed to study 
sumoylation, there is an unmet need for a modern and systematic analysis of paralog-
specific SUMO substrates. Identifying substrates that are preferentially modified by 
SUMO1 or SUMO2/3 could improve our overall understanding of the important 
biological processes that they regulate. However, it is important to note that 
modification by SUMO1 or SUMO2/3 on the same protein can also have diverse 
functional effects, thus identifying proteins that can be modified by multiple paralogs 
is also of interest. As discussed in the following sections, SUMO modification of 
overlapping or unique paralog specific substrates regulates many important cellular 
processes, including the stress response, DNA repair, nuclear body integrity, mitosis 
and transcription.  
 
SUMO Paralogs and the Stress Response 
 
Many SUMO2/3 modified proteins are involved in the cellular stress response. This 
was first observed when vertebrate cells heat shocked at 43°C displayed a large 
increase in SUMO2/3 modified proteins and a corresponding decrease in free 
SUMO2/3, revealing that previously unmodified proteins were being conjugated by 
SUMO2/3 upon heat shock. Moreover, upon recovery at 37°C, conjugated and free 
SUMO2/3 levels went back to pre-stress levels, revealing that SUMO2/3 modification 
of proteins in response to heat shock is reversible. In contrast, levels of free and 
conjugated SUMO1 did not change upon heat shock treatment. However, most 
SUMO1 is already conjugated under normal growth conditions, thus the role of 




To see whether the increased SUMO2/3 modification of proteins was specific to heat 
shock, or a conserved reaction among other stressors, cells were also treated with 
hydrogen peroxide as an oxidative stressor, or ethanol and sodium chloride as osmotic 
stressors. Consistent with general stress response functions, an increase in SUMO2/3 
conjugated proteins, similar to those obtained under heat shock conditions, was 
observed (178). Proteins modified in response to various stressors have been 
identified as factors involved in apoptosis, folding and degradation of proteins and DNA 
repair, among others (179, 180). These factors are often preferentially modified by 
poly-SUMO2/3 chains, where they serve as signals for ubiquitylation and degradation, 
or conversely, as signals for stabilizing protein complexes (10, 180). For instance, 
poly-SUMO2/3 chains stabilize protein complexes involved in gene expression and 
post-transcriptional modification of mRNAs coding for survival factors in response to 
heat shock (180).  
 
Accumulation of misfolded or mis-targeted proteins in the endoplasmic reticulum (ER) 
is a consequence of proteotoxic stress. An important protein quality control 
mechanism to prevent this is ER-associated degradation (ERAD), where misfolded 
proteins in the ER are delivered to the cytoplasm for proteosome degradation (181). 
The ubiquitin specific protease 25 (USP25) is a component of the ERAD pathway and 
can be sumoylated with both SUMO1 and SUMO2/3. However, USP25 is more 
efficiently modified by SUMO2/3 due to a higher affinity interaction of the USP25 SIM 
with SUMO2/3, and there is evidence that USP25 is modified by poly-SUMO2/3 chains 
(47, 182). The functional consequence of poly-SUMO2/3 modification is impaired 
binding and hydrolysis of ubiquitin chains, though the consequence of this specifically 
in ERAD has not been established (47). Lastly, an important protein known to be 
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affected by ERAD is the cystic fibrosis related protein, CFTR (183). Interestingly, 
CFTR can also be modified by both SUMO1 and SUMO2/3, however the functional 
consequences of the different modifications appear to be unique. For instance, it is 
suggested that SUMO1 modification stabilizes CFTR, whereas modification by 
SUMO2/3 targets the misfolded protein for RNF4-mediated proteasomal degradation 
(184). Taken together, this reveals that poly-SUMO2/3 chains act as recruitment 
signals with diverse biological outcomes, such as stabilization or degradation of 
proteins and protein complexes. The spatiotemporal requirement for polymeric-
SUMO2/3 chains in various biological capacities is not fully understood and therefore 
requires further exploration. 
 
SUMO Paralogs and DNA Repair 
 
Many cellular stressors cause damage to DNA. Consistent with the role of poly-
SUMO2/3 chains acting as a stress response signal, the chains also serve to recruit 
repair factors to sites of DNA lesions (10). For instance, DNA damage caused by UV 
irradiation promotes the formation of poly-SUMO2/3 chains on the ATRIP repair factor 
(185). Sumoylated ATRIP enhances its localization to sites of DNA damage. 
Moreover, poly-SUMO2/3 chains facilitate ATRIP interactions with other repair factors, 
such as ATR, replication protein A 70 (RPA70) and the MRN complex, thereby 
facilitating the DNA repair process (185, 186). Since poly-SUMO2/3 chains interact 
with SIMs in RNF4, sumoylation also enhances the degradation of DNA repair 
proteins, such as MDC1 and RPA (69). This is a critical step in DNA repair because 
RPA needs to be replaced by homologous recombination factors, which is facilitated 
by the SUMO-dependent proteasomal degradation of RPA (69).  
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The Bloom syndrome protein, a RecQ related DNA helicase (BLM) is also involved in 
homologous recombination and DNA repair, where it helps repair damaged replication 
forks (187). Our lab has shown that BLM is preferentially modified by SUMO2/3, as 
compared to SUMO1, in vitro and in vivo (188, 189). This paralog-selective 
sumoylation is determined by two BLM SIMs that preferentially bind non-covalently to 
SUMO2 relative to SUMO1. The non-covalent interaction between SUMO2 and BLM 
likely enhances the interaction of SUMO2-charged Ubc9 with BLM, thus leading to its 
preferential modification by SUMO2 (188). Sumoylation regulates BLM function in 
repairing stalled replication forks through mediating protein-protein interactions with 
Rad51, another DNA repair protein. Interestingly, Rad51 was found to bind equally 
and non-covalently to both SUMO1 and SUMO2, and SUMO2 was shown to have a 
strong positive effect on BLM binding to Rad51 (data on SUMO1 was not reported) 
(187). In summary, through modification of a diverse set of proteins, or through diverse 
functional outcomes through modification of the same protein, the SUMO paralogs are 
important regulators of DNA repair.  
 
SUMO Paralogs and Nuclear Bodies 
 
Nuclear bodies are distinct, membrane-less nuclear microenvironments enriched with 
functionally related proteins that carry out specific processes (190). The promyelocytic 
leukemia nuclear body (PML-NB) is found in most cell lines and many tissues. 
Although the precise function of PML-NBs is complex, they contribute to the regulation 
of transcription factor activity, maintenance of genome stability and antiviral responses 
(58, 59, 62, 191). While the PML protein is the defining component of PML-NBs, 
SUMO1 and SUMO2/3 are also important resident proteins (190). Of functional 
importance, the PML protein has three sumoylation sites that allow for modification by 
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SUMO1, SUMO2 and SUMO3, and a SIM that facilitates non-covalent interactions 
with other SUMO-modified resident PML-NB proteins (190, 192). Sumoylation 
regulates the formation of PML-NBs through a “seeding” mechanism, whereby SUMO 
and SUMO-modified PML serve as nucleators that initiate formation (192). Beyond its 
role in PML-NB formation, sumoylation also regulates PML-NB integrity. For instance, 
loss of sumoylation leads to a decrease in PML-NBs in embryonic cells derived from 
Ubc9 knockdown mice and from SUMO1 KO mice (63, 66).  
 
As introduced in Chapter 1, PML fused to RARα forms an oncogenic protein that 
initiates acute promyelocytic leukemia, which is successfully treated with arsenic 
trioxide (86, 89, 193). Intriguingly, SUMO1 and SUMO2/3 have unique contributions 
in the arsenic-triggered degradation of PML-NBs. For instance, loss of SUMO1 delays 
arsenic-induced PML degradation and stabilizes PML conjugates, revealing that 
SUMO2/3 cannot compensate for the loss of SUMO1 in this process. Conversely, loss 
of SUMO2/3 leads to increased arsenic-induced PML degradation and a loss of PML 
conjugates. When both SUMO1 and SUMO2/3 were knocked-down simultaneously, 
neither PML conjugates nor arsenic-induced degradation was observed (85). Taken 
together, these findings reveal that SUMO1 and SUMO2 non-redundantly regulate 
arsenic-induced degradation of PML. Consistently, we also reveal non-redundant 
functions for SUMO1 and SUMO2 in PML-NB integrity, as explored in the following 
chapter.  
 
The death-associated protein 6 (DAXX) is a transcriptional repressor, and also another 
resident protein of PML nuclear bodies. DAXX can be modified by both SUMO1 and 
SUMO2, though it preferentially binds SUMO1, as demonstrated through in vitro 
binding assays and NMR structural studies (194, 195). The preference for non-
 62 
covalent binding of SUMO1 is enhanced by the phosphorylation of serine residues that 
flank a SIM in DAXX, and this SUMO1-SIM interaction helps promote the preferential 
conjugation of SUMO1 to DAXX (196). Functionally, sumoylation affects the 
localization of DAXX to condensed chromatin and to transcription factors such as 
Smad4, the androgen receptor and the glucocorticoid receptor (GR). Intriguingly, and 
as discussed in more detail below, SUMO modification represses the activity of these 
transcription factors, suggesting that SUMO modified DAXX may have a role in 
transcriptional repression. Indeed, both reporter and endogenous gene expression 
assays using a DAXX SIM mutant found that DAXX inhibits GR transcriptional activity 
through binding to SUMO-modified GR (195). In summary, it is clear that SUMO1 and 
SUMO2/3 are each important in regulating nuclear body components. However, 
whether the paralogs have unique and non-redundant roles in nuclear body integrity, 
and what these unique roles are, remains to be answered. In the following chapter, we 
examine nuclear body integrity in SUMO1 and SUMO2 knock out cells and reveal 
evidence for non-redundant paralog-specific roles. 
 
SUMO Paralogs and Mitosis 
 
Sumoylation is essential for proper chromosome segregation in eukaryotes ranging 
from yeast to humans. This has been demonstrated in human cells using a global 
SUMO inhibitor, which results in the cells failing to complete cell division due to mitotic 
defects (197). This finding is also consistent with studies using shRNA or RNAi 
knockdown of SUMO conjugating enzymes (64, 198). With regard to paralog-specific 
functions in this process, our lab has revealed that SUMO1 and SUMO2/3 have unique 
localizations to chromatin during mitosis. For instance, SUMO1 localizes to the mitotic 
spindle and spindle midzone, whereas SUMO2/3 localizes to centromeres and 
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condensed chromosomes (198). These differences in localization suggest that 
different sets of proteins are being modified by SUMO1 and SUMO2/3 during mitosis. 
In line with this, SUMO1 is required for RanGAP1 localization to the mitotic spindle 
during metaphase (199). Furthermore, our lab has found that the centromere-
associated protein E (CENP-E), BubR1 and Nuf2 kinetochore-associated proteins are 
modified selectively by SUMO2/3, but not SUMO1. In the case of CENP-E, this 
modification is dependent upon intact CENP-E SIMs that bind non-covalently to 
polymeric-SUMO2/3 chains, which are essential for proper CENP-E localization and 
functions at kinetochores (198). A subsequent group later found that sumoylation 
regulates the stability of the kinetochore through reversible SUMO2/3 modification of 
the CENP-H/I/K complex. Regulation of this complex is mediated by competing 
activities of the SUMO protease SENP6, and the SUMO targeted ubiquitin ligase, 
RNF4. In the absence of SENP6, RNF4 recognizes the poly-SUMO2/3 chains and 
subsequently ubiquitylates and targets CENP-I for proteasomal degradation. 
Conversely, through deconjugating poly-SUMO2/3 chains from CENP-I, SENP6 
prevents RNF4 mediated degradation of the CENP-H/I/K complex, thereby stabilizing 
the kinetochores (32). Having intact kinetochores is required for the proper alignment 
of chromosomes to the metaphase plate, thus, SUMO2/3 is an important regulator of 
this process (32, 198).  
 
Of relevance, our lab also recently found that a subunit of another critical mitotic 
regulator, the anaphase promoting complex 4, is sumoylated by both SUMO1 and 
SUMO2/3. However, our findings that sumoylation is required for a timely transition 
from metaphase to anaphase did not systematically compare the effects of the 
paralogs during this process (200). Given the evidence for diverse paralog-specific 
signals in regulating large complexes of proteins, it would be interesting to further 
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investigate the roles of the individual paralogs in regulating the anaphase promoting 
complex. In summary, the effects of sumoylation are complex. Beyond acting as 
signals for recruitment or localization, they can also act as stabilization or degradation 
signals, though an enhanced understanding of this requires further study.  
 
SUMO Paralogs and Chromatin 
 
Sumoylation has important roles in regulating chromatin structure, gene expression 
and genome integrity (201-204). Although, the individual contributions of the SUMO 
paralogs in these processes are not fully defined, evidence suggests the existence of 
paralog-specific functions. For instance, SUMO1 and SUMO2 are both associated with 
chromatin, as observed by chromatin immunoprecipitation coupled to DNA 
sequencing (ChIP-seq) in WI38 human fibroblasts. While both paralogs were heavily 
enriched at transcription start sites (TSS) in these cells, only 2/3 of all identified sites 
were enriched with both SUMO1 and SUMO2. Thus, 1/3 of identified SUMO1 binding 
sites in these cells were unique to SUMO1, and similarly, ~1/3 of identified SUMO2 
sites were unique to SUMO2. Consistent with SUMO paralogs having unique 
functions, these findings reveal that a large portion of genomic sites display unique 
associations with SUMO1 or SUMO2 (202). Of note, many of the loci bound by 
SUMO1 and SUMO2 in this study coded for histone and protein biogenesis genes, 
where sumoylation was found to be repressive based on gene expression profiling. 
Consistently, another ChIP-Seq study also found that SUMO1 is enriched at TSS of 
genes coding for ribosomal protein subunits and translation factor genes (205). 
However, this study found that SUMO1 is associated with transcriptional activation of 
these genes. Mechanistically, it was identified that SUMO1 modification of the scaffold 
attachment factor B recruits polymerase II to these genes, thus enhancing their 
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transcription (205, 206). In Chapter 3, we analyze the transcriptome of SUMO1 and 
SUMO2 KO cells and find that the most differentially expressed genes in the SUMO1 
KO cells are repressed, consistent with an activating role for SUMO1 in gene 
expression.   
 
SUMO Paralogs and Transcription 
 
Sumoylation is an important regulator of gene expression (201, 207-209), as 
demonstrated by the hundreds of transcription factors (TF) and chromatin remodeling 
proteins that are SUMO substrates (175, 210). A number of early studies evaluated 
the effects of either SUMO1, SUMO2 or SUMO3 modification on transcription factor 
function, but they often did not directly compare the effects of individual paralogs. 
However, the handful of studies that did investigate signaling capabilities of SUMO 
paralogs provided functional evidence for paralog-specific effects. Taken together, 
these findings defined a few common themes surrounding the effects of SUMO 
paralogs in regulating gene expression, as detailed below. 
 
Early explorations of the functional consequences of SUMO-modified transcription 
factors often revealed a repressive phenotype (208, 211, 212). For instance, the Sp3, 
p300 and c-Jun transcription factors, and androgen and glucocorticoid receptors were 
all repressed when modified by SUMO1 (211, 213-215). As noted in Table 1, many of 
these studies either did not evaluate the effects of SUMO2 or SUMO3, or did not follow 
up on the functional implications of the other SUMO paralogs modifying these TFs. 
Thus, the findings from these studies did not necessarily indicate that SUMO1 uniquely 
functions as a repressive modifier, though it was thought to be for many years. In 
contrast, subsequent studies found that the p53 and CMV IE2-p86 transcription factors 
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are activated upon SUMO1 modification. The opposing effects of SUMO modification 
on TFs suggested that the effects may be context dependent (216, 217).   
 
For instance, the corepressor for the DNA-binding protein REST (CoREST1) binds 
directly and noncovalently to SUMO2, but not SUMO1. As CoREST1 bridges binding 
between a lysine-specific histone demethylase and deacetylase, SUMO2 modification 
of unknown factors facilitates formation of a repressive complex that alters chromatin 
structure and gene expression (218). Moreover, although early studies of the 
androgen receptor (AR) in prostate cancer cell lines found that it was SUMO1 
modified, it was subsequently found to be modified by SUMO1, 2 and 3 using 
overexpression conditions. Interestingly, the paralogs had different effects on 
transcription depending on the cell line. For instance, while SUMO1 and SUMO3 had 
a negative effect on AR transactivation in a prostate cancer cell line derived from bone 
metastases that lack an endogenous androgen receptor (PC-3), SUMO2 did not have 
an effect. In contrast, in prostate cancer cell lines that express endogenous AR 
(LnCap), SUMO2 and SUMO3 enhanced AR transactivation whereas SUMO1 had no 
effect (100).  
 
Lastly, studies using gene fusion-reporter assays in cell culture found that SUMO2 has 
a stronger intrinsic repression activity than SUMO1 both in cis and in trans (54, 178, 
215). Intriguingly, these functional differences are attributed to conserved basic 
residues found on the exposed Ub-fold of both SUMO1 and SUMO2. Mutations in 
these residues leads to a similar increase in reporter activity for both SUMO paralogs, 
suggesting that they utilize a structurally similar surface to mediate their effects on 
transcription (54). However, differences in surrounding residues must alter the 
molecular and structural environment enough to impart paralog-specific functional 
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differences, since SUMO1 does not inhibit transcription to the same extent as SUMO2. 
Consistent with this, it was found that a “hydrophobic hole”, formed between the B-
sheet and a-helix, is substantially deeper and shifted in SUMO1 as compared to 
SUMO2. Thus differences in the shape and location of this cavity may contribute to 
the lower intrinsic repression potential of SUMO1 as compared to SUMO2, though this 
remains to be formally tested (54). Also of note, the repressive effect of SUMO2/3 is 
independent of its ability to form chains, as mutations of the internal consensus motif 
do not affect transcriptional repression activity (215).  
 
How are the SUMO paralogs able to regulate the expression of such diverse TFs? A 
few mechanisms of action have been described (201), and they are consistent with 
the ability of SUMOs to mediate both covalent and non-covalent protein-protein 
interactions (Figure 4). For instance, sumoylation consensus sites for conjugation 
have been identified in the inhibitory domains of many TFs. The consequence of 
SUMO modification at these sites is the formation of a new interaction surface which 
recruits transcriptional regulators, often found to be repressors, to the TF (211). 
Moreover, sumoylation also recruits transcriptional regulators to regulatory elements 
within genes. For instance, eukaryotic genes are surrounded by activating and 
repressing regulatory elements, which are also regulated by activating and repressing 
multi-protein complexes. These regulatory elements function in concert, resulting in 
robust gene expression changes, and are thus termed synergy control (SC) motifs 
(214). Consistent with sumoylation bringing together protein complexes, such as the 
ones involved in transcriptional repression, these SC motifs contain sumoylation 
consensus sites (215). Modification by SUMO paralogs within these SC motifs 
selectively inhibits synergistic activation, as demonstrated by enhanced activity upon 
disruption of acceptor lysines in hormone receptors and TFs (214, 215, 219). Lastly, 
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chromatin remodeling factors are recruited to promoters in a SUMO-dependent 
manner (212). This includes important regulators such as histone deacetylases 
(HDAC1, 2 and 4), histone demethylases (LSD1), histone methyltransferase 
(SETDB1), lysine specific demethylases (KDM5B and KDM5C) (18), nucleosome 
remodeling ATPases (Mi-2) and chromatin-associated proteins (HP1 and L2MBTL1) 
(212). This recruitment is driven through non-covalent interactions of SUMOs with 
SIMs in the chromatin modifying enzymes. Taken together, these findings suggest that 
sumoylation plays a central role in coordinated histone modifications and chromatin 
structure important for regulation of gene expression (207). 
 
Although early studies suggested a repressive phenotype associated with SUMO 
modification of TFs, subsequent studies revealed more complex regulation, 
suggesting that the effects of the paralogs on sumoylation are context dependent. 
More recently, it has also been suggested that sumoylation of TFs may function 
upstream of bringing together repressor and corepressor complexes. Specifically, it 
has been suggested that sumoylation facilitates interactions between TFs and specific 
chromatin loci (217). This idea is based on the finding that in the absence of 
sumoylation, eukaryotic TFs bind to numerous non-specific sites, suggesting that 
sumoylation aids in binding site selection (217, 220). Taken one step further, it has 
been suggested that prior to TF sumoylation, TFs bind promiscuously and with 
reduced specificity throughout the genome. This ensures that all functional sites 
become bound, but then is reliant, in part, upon sumoylation to either increase the 
specificity of binding, or to promote the release of the TF through mediation of protein-
protein interactions (217). Sumoylation could affect TF conformation and DNA binding 
affinity, as proposed for the turnover of TDG from DNA abasic sites (73), or to promote 
interactions with other factors that influence DNA binding. In either case, sumoylation 
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acts as a specificity factor for TF binding. More work is required to understand the 
roles of the individual paralogs in this process. To that end, we performed a systematic 
analysis of the global effects of gene expression in the absence of SUMO1 or SUMO2 
and identified unique and non-redundant roles for the paralogs in transcription 
regulation, as described in Chapter 3.  
 
Caveats to Human Cell Culture and In Vitro Experiments 
 
As mentioned, early studies of sumoylation focused on the role of a single SUMO 
paralog, such as SUMO1 or SUMO2/3, on a particular protein of interest. Furthermore, 
these studies followed a somewhat generic, yet consistent, workflow in which proteins 
of interest were shown to be modified by SUMO1 or SUMO2/3 using 
immunoprecipitation assays and western blots. Next, many researchers then identified 
the modified residue using targeted mutational studies, which involved changing the 
presumed lysine to an arginine or other amino acid. A caveat to this approach is that 
many PTMs modify lysines, including acetylation, ubiquitylation, and sumoylation (by 
the other SUMO paralogs) (208). Thus, observed downstream affects could potentially 
be due to the loss of other affected PTMs.  
 
Moreover, to explore the function of SUMO on the modified protein of interest, mutant 
proteins were often tagged and then overexpressed in cells. For instance, 
exogenously tagged SUMO paralogs, mutant forms of SUMO paralogs and tagged or 
mutant SUMO substrates were often overexpressed in many of the highlighted 
studies. There are numerous caveats to these experimental designs. First, an obvious 
issue is the use of mutant or tagged proteins, which may not accurately recapitulate 
what the non-mutant, wildtype (WT) proteins are doing in human tissues or cells. For 
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instance, mass spectrometry analysis of SUMO paralogs and SUMO targeted proteins 
is often performed using an expressed His-tagged form of SUMO. Although this 
provides high yields of SUMO modified proteins for MS identification, elevated levels 
of SUMO may behave differently than endogenous levels (36). Additionally, these tags 
or mutations might create or abolish binding and interaction domains, subcellular 
localizations, or normal protein activity. Moreover, there are known artifacts associated 
with overexpression studies, such as unequal expression of the exogenous protein 
across cells, which could potentially mask or exaggerate phenotypes. Consistent with 
this, transient knockdowns, which were also used in many of the highlighted studies, 
often do not completely rid the biological system of the protein of interest, meaning 
incomplete or masked phenotypes may be present under these conditions. Lastly, 
although many studies used in vitro assays to demonstrate target protein sumoylation, 
this finding may not recapitulate in vivo requirements for a specific paralog. This is 
exemplified by RanGAP1, which as previously mentioned, is preferentially modified by 
SUMO1 in vivo (6), but can be also modified by SUMO2 in vitro (47, 50). 
 
To circumvent many of these concerns, the work presented in the next two chapters 
explores endogenous expression levels of genes and proteins, as much as possible. 
This is paired with large scale sequencing studies from human patients, and knockout 
studies using CRISPR-Cas9 technology. Importantly, and differing from many of the 
early studies, we used a systematic approach in our discovery of unique and non-
redundant SUMO paralog specific functions. However, we also acknowledge the 
inherent issues with CRISPR-Cas9 and other caveats to our study design, as 






In summary, many essential cellular processes, from ER-associated degradation in 
the cytoplasm to transcription in the nucleus, are regulated by proteins that are 
selectively modified by SUMO1 or SUMO2/3. These proteins are recognized as 
substrates for paralog-specific modification at the level of the E3 ligases and SUMO 
proteases, as well as through non-covalent interactions of substrate proteins with 
SIMs. The functional outcomes of these paralog specific modifications are complex 
and have important and vastly different biological consequences (Figure 4). Enhancing 
our understanding of the spatiotemporal regulation and consequences of SUMO 
paralog modification is important to understanding both the diverse cellular effects of 








Figure 6. SUMO proteins are conserved across eukaryotic model organisms. The 





Figure 7. Key residues of SIM interaction domains involved in transcriptional regulation.      
3-D structures of SUMO1 (left) and SUMO2 (right). The highlighted residues have been 
implicated in transcriptional repression. Specifically, the four basic residues in SUMO2 (K33, 
K35, K42 and R50, blue) were identified as critical for transcriptional inhibition using a linear 
non-cleavable fusion of SUMO2 to a Gal4 promoter (54). Analogous residues are found in 
SUMO1, as labeled. Of note, the SUMO1 structure includes two additional amino acids (GS) 
at the N-terminus, and also contains the precursor residues at the C-terminus (GSTV), as 
marked with a dashed line. In contrast, the SUMO2 structure is the complete processed 















Sp3 SUMO1 Repression Alters localization No (211) 
c-Jun SUMO1 Repression N/A No (70) 
p300 SUMO1 Repression HDAC6 recruitment SUMO2,3* (215, 221) 





p53 SUMO1 Activation N/A No (223, 224) 






SC motif** No / SUMO2,3 
(213) / (100, 
220) 
Glucocorticoid 
Receptor SUMO1 Repressive SC motif** SUMO2 (226, 227) 
cEBP/α SUMO1 Repressive SC motif** SUMO3* (203, 228) 
HSP2 SUMO1 N/A Alters DNA binding SUMO2* (229) 
CMV-IE2-p86 SUMO1 Activation Alters protein interactions SUMO2/3* (209) 
Elk-1 SUMO1 Repressive  Alters Localization SUMO1,2,3* (230) / (231) 
CoREST1 SUMO2 Repression 
Localizes LSD1 
& HDAC at 
promoters 
SUMO1  (218) 
FOXC1 SUMO2/3 Repression SC motif** SUMO1* (232) 





Ikaros SUMO1 Activation Alters binding with repressors No (233) 
* Authors demonstrated that TF could be modified by other paralogs, and did not 
explain why they chose to focus on the selected paralog for downstream studies.  









Chapter 3: Characterization of Human SUMO 
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The small ubiquitin-related modifiers (SUMOs) regulate nearly every aspect of cellular 
function, from gene expression in the nucleus to ion transport at the plasma 
membrane. In humans, the SUMO pathway has five SUMO paralogs with sequence 
homologies that range from 45% to 97%. SUMO1 and SUMO2 are the best studied 
paralogs, and also the most distantly related. To what extent SUMO1, SUMO2 and 
the other paralogs impart unique and non-redundant effects on cellular functions, 
however, has not been systematically examined and is therefore not fully understood. 
Knockout studies in mice have revealed conflicting requirements for the SUMO 
paralogs during development and studies in cell culture have relied largely on transient 
paralog overexpression or knockdown. To address the existing gap in understanding, 
we first analyzed SUMO paralog gene expression levels in normal human tissues and 
found unique patterns of SUMO1-3 expression across 30 tissue types, suggesting 
paralog-specific functions in adult human tissues. To systematically identify and 
characterize unique and non-redundant functions of the SUMO paralogs in human 
cells, we next used CRISPR-Cas9 to knock out SUMO1 and SUMO2 expression in 
osteosarcoma (U2OS) cells. Analysis of these knockout cell lines revealed specific 
functions for SUMO1 and SUMO2 in regulating cellular morphology, PML nuclear body 
structure, responses to proteotoxic and genotoxic stress, and control of gene 
expression. Collectively, our findings reveal non-redundant regulatory roles for 
SUMO1 and SUMO2 in controlling essential cellular processes and provide a basis for 





Small ubiquitin-related modifiers (SUMOs) function as post-translational protein 
modifications that regulate a broad range of cellular functions including chromosome 
segregation, DNA damage repair, gene expression, cellular stress responses, 
mitochondrial fission and ion channel activity (234). At the molecular level, many 
similarities exist between the SUMO and ubiquitin protein modification pathways. Like 
ubiquitin, SUMOs are conjugated to other proteins through an enzymatic cascade 
involving an E1 activating enzyme, an E2 conjugating enzyme, and E3 ligases. 
Sumoylation of most proteins is also highly dynamic and reversible through the action 
of SUMO-specific isopeptidases. Similar to ubiquitin, SUMO is also recognized as a 
cellular signal and promotes protein-protein interactions between modified substrates 
and downstream effector proteins. However, the SUMO and ubiquitin pathways 
diverge at the level of the modifying proteins themselves. In contrast to a single 
ubiquitin protein, most multicellular organisms, including plants, vertebrates and basal 
insects, express multiple SUMO paralogs (151, 155, 235). Despite their expansion and 
conservation across species, the functional significance of SUMO paralogs and why 
they evolved remains an important question for the field. 
 
Humans express five SUMO paralogs, SUMO1-5, that share 45-97% sequence 
identity. Of the paralogs, SUMO1-3 are the most widely studied. Following processing, 
SUMO2 and SUMO3 share ~97% peptide sequence identity and are thus often 
referred to as SUMO2/3. In contrast, SUMO1 shares only ~45% sequence identity with 
SUMO2/3, suggesting that these paralogs may have unique properties and can be 
recognized as distinct signals. Consistent with this, a number of studies have identified 
proteins that interact preferentially with SUMO1 or SUMO2/3 through variant SUMO 
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interacting motifs (SIMs) (188, 198, 218). In addition, SUMO2/3 contains an internal 
consensus site lysine at position 11 that allows for efficient assembly of SUMO2/3 
polymeric chains (38). Among other possible functions, SUMO2/3 polymeric chains 
are recognized by SUMO targeted ubiquitin ligases, and can thereby target proteins 
for degradation through the ubiquitin-proteasome system (39, 40). SUMO1 lacks a 
consensus site lysine and thus has reduced potential to form polymeric chains. The 
ability to associate differentially with SIM-containing proteins and to form polymeric 
chains may be defining features that distinguish SUMO1 from SUMO2/3 function, 
although this remains to be formally tested. SUMO4 and SUMO5 are the least well 
understood, and limited studies suggest that both paralogs have restricted expression 
to specific tissues (43, 46). As such, our work primarily focuses on the SUMO1-3 
paralogs.   
 
At the organismal level, genetic knockout studies in vertebrates have provided 
conflicting results on the essential functions of individual SUMO paralogs. Whereas 
SUMO1 expression is uniquely required for development in Xenopus laevis, SUMO1, 
SUMO2 and SUMO3 are each dispensable for development in zebrafish (236). In 
mice, SUMO2 is essential for embryonic development, but SUMO3 is not (155). 
Moreover, functions for SUMO1 in mice are less clear, as it has been reported to be 
both critical and dispensable for embryonic development (157-159). Studies focused 
on the roles of the paralogs in development are further complicated by the fact that 
they do not reveal possible essential functions post-development. In this regard, 
otherwise normal SUMO1 knockout mice have dramatically different responses to a 
high fat diet (160). Consistently, unique roles for the SUMO paralogs post-embryonic 
development are supported by studies at the tissue level, including in the placenta, 
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intestine, eye and brain. In each of these tissues, SUMO1 and SUMO2/3 exhibit 
remarkably different expression and localization patterns (237, 238).  
 
At the cellular level, numerous studies have also documented SUMO1 and SUMO2/3 
specific effects on gene regulation. For instance, SUMO2/3, but not SUMO1, regulates 
a repressive complex that mediates chromatin structure and transcriptional changes 
that are important for cell-type specific gene expression (218). Moreover, it was 
reported that fusing SUMO1 or SUMO2 to the glucocorticoid receptor differentially 
affects transcription activation in transfected cells (215). Other lines of evidence 
supporting non-redundant roles for SUMO1 and SUMO2/3 in regulating cellular 
functions include their unique subcellular localizations and dynamics in cultured 
mammalian cells (198-200), apparent differential activation by cellular stress (178), 
evolution of paralog-specific E3 ligases and isopeptidases (10, 13, 166, 169), and 
identification of distinct target substrates through proteomic studies (19). It should be 
noted that one limitation of many of these studies has been a reliance on protein 
overexpression. Collectively, the available data justify a more detailed characterization 
of SUMO paralogs and their functions. 
 
In this study, we analyzed SUMO paralog expression levels in human tissues and cell 
lines using publicly available gene expression data and found supporting evidence for 
paralog-specific functions across a wide range of normal human tissues. Using the 
CRISPR-Cas9 system, we knocked out SUMO1 and SUMO2 paralog expression 
individually in human U2OS cells. Systematic analysis of these knockout cell lines 
revealed unique and non-redundant functions for SUMO1 and SUMO2 in control of 
cell morphology, stress responses, PML nuclear body assembly and gene expression. 
Together, our findings provide insights into unique and non-redundant functions of 
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SUMO1 and SUMO2 in human cells and provide a foundation for further exploration 




Evaluating SUMO Paralog Expression in Human Tissues and Cell Lines 
 
Functional contributions of the SUMO paralogs may be reflected in their relative 
expression levels across various cell lines and tissues. We therefore turned to publicly 
available data repositories to explore SUMO1-4 gene expression levels and patterns 
in approximately 500 cell lines and 30 human tissues. We first turned to the Broad 
Institute’s Cancer Cell Line Encyclopedia (CCLE) (239) to explore SUMO1-4 
expression in cancer cell lines derived from bone, breast, liver, lung, ovary, pancreas 
and thyroid tissues. We found that SUMO2 expression was consistently ~37% higher 
than SUMO1 and SUMO3, which had similar levels (Figure 8A). In addition, the relative 
expression values of the paralogs across cell lines were similar, despite varying tissue 
origins. Of note, SUMO4 was consistently expressed at near-zero levels, and thus is 
not shown. Since our studies involve U2OS osteosarcoma cells, as described below, 
we specifically looked at SUMO1-4 levels in bone cancer cell lines and U2OS cells. 
Here, we found expression patterns and values consistent with those from the other 
analyzed cancer cell lines (Figure 8B, U2OS in insert).  
 
We next compared SUMO1-4 gene expression levels in normal human tissues using 
data from the Genotype-Tissue Expression (GTEx) project. In contrast to observing 
consistent paralog expression patterns across cancer cell lines, human tissue data 
revealed varying levels of paralog expression across tissue and organ types (Figure 
8C). Notably, although SUMO4 has been reported to have tissue-specific expression 
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in the kidney (42) and in lymph nodes, we found near-zero levels in all analyzed 
tissues, including the kidneys; data from lymph nodes was not available (Supplemental 
Figure 1). SUMO1-3, however, has varying expression levels. For instance, we found 
that SUMO1 expression was higher than SUMO2 in 10 of the 30 analyzed tissues, 
with the largest difference in expression occurring in the liver, followed by the adrenal 
gland and muscle (Figure 8D). SUMO2 expression was higher than SUMO1 in 16 of 
the 30 tissues, with noticeably elevated levels in reproductive organs, such as the 
ovaries, uterus, cervix uteri, vagina, fallopian tube, and the testis. Of note, many of the 
reproductive tissues had the lowest numbers of available samples, as labeled in Figure 
8D. Lastly, SUMO3 expression levels were higher than both SUMO1 and SUMO2 in 
23 of the 30 analyzed tissues. These varying patterns of SUMO1-3 expression suggest 
non-redundant, paralog-specific functions in adult human tissues. 
 
Generation of SUMO1 and SUMO2 KO Cells using CRISPR-Cas9 
 
To allow for a more systematic identification and characterization of unique and non-
redundant functions of SUMO paralogs in human cells, we used the CRISPR-Cas9 
system to individually knock out SUMO1 and SUMO2 expression in U2OS human 
osteosarcoma cells. Of the highly similar SUMO2 and SUMO3 paralogs, we chose to 
focus on SUMO2 given its apparent higher level of expression compared to SUMO3 
in human cell lines and subsequent supporting evidence that SUMO3 protein levels 
are low in U2OS cells (Figure 8A, Figure 9C). We confirmed heterozygous biallelic 
SUMO gene knockouts using Sanger DNA sequencing (Figure 9A, Supplemental 
Figure 2, Supplemental Figure 3). More precisely, we confirmed a deletion of the first 
exon that interfered with transcription initiation in both alleles of the SUMO1 gene, and 
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the creation of a premature stop codon in the second exon of both SUMO2 alleles in 
the respective KO cells.  
 
RNA-sequencing analysis revealed that paralog mRNA expression patterns in WT 
cells were similar to those observed in other cancer cell lines using data from CCLE. 
Specifically, we found that SUMO2 was the most highly expressed paralog, followed 
by SUMO1 and SUMO3, and lastly SUMO4, which had negligible expression (Figure 
9B). In the SUMO1 KO cells, SUMO1 mRNA decreased by >99% as compared to WT 
values, with a very small increase in SUMO2 (< 3%) and a two-fold decrease in 
SUMO3. In the SUMO2 KO cells, we observed a 65% decrease in SUMO2 signal as 
compared to values in WT cells. Based on observed protein levels (below), we 
hypothesize that the higher than expected levels of SUMO2 mRNA may be due to 
detection of mutant transcripts (Figure 9A and B). Also of note, we observed a 17% 
increase in SUMO1 and a 63% increase in SUMO3 mRNA expression in the SUMO2 
KO cells.  
 
To evaluate SUMO1 and SUMO2/3 protein expression in the KO cells, we used 
immunoblot and immunofluorescence microscopy assays with SUMO1 and SUMO2/3 
specific antibodies. Both assays revealed undetectable levels of SUMO1-modified 
proteins and severely diminished levels of SUMO2/3-modified proteins in the 
respective KO cell lines (Figure 9C and D). Since the SUMO2/3 antibody recognizes 
an epitope common to both SUMO2 and SUMO3 (198), residual signal in the SUMO2 
KO cells is a likely indicator of the relatively low level of SUMO3 protein expression. 
Taken together, we generated viable cell lines with undetectable levels of SUMO1 
protein expression and severely reduced levels of SUMO2/3 expression.  
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Characterization of Morphological Changes of SUMO KO Cells 
 
Immunofluorescence microscopy revealed unique changes in the morphology of 
SUMO2 KO cells as compared to WT and SUMO1 KO cells (Figure 9D). Specifically, 
~50% of SUMO2 KO cells exhibited a fibroblast-like morphology with an elongated 
and bipolar shape that contrasted with the primarily polygonal and epithelial-like WT 
and SUMO1 KO cells. Notably, fewer than 5% of WT and SUMO1 KO cells exhibited 
a fibroblast-like morphology (Figure 10A). To investigate whether the change in 
morphology was due specifically to the loss of SUMO2, we constructed SUMO2 KO 
rescue cell lines with stable, constitutive SUMO2 re-expression or SUMO1 
overexpression by plasmid transfection and single-cell cloning. SUMO2 and SUMO1 
protein levels in the rescue cell lines (S2KO+S2 and S2KO+S1, respectively) were 
assessed by immunoblotting and immunofluorescence microscopy (Figure 10B and 
C). Semi-quantitative measurements of relative SUMO protein levels revealed a near 
complete restoration of SUMO2/3 expression in the S2KO+S2 cells and a near two-
fold increase in SUMO1 expression in the S2KO+S1 cells as compared to endogenous 
WT levels. A visual inspection of the rescue cell lines by immunofluorescence 
microscopy revealed that re-introduction of SUMO2 appeared to restore the epithelial-
like morphology of WT cells, whereas SUMO1 overexpression had no effect (Figure 
10A and D).  
 
To assess the morphological changes of the knockout and rescue cell lines more 
quantitatively, we used FIJI image processing software (240) to analyze the average 
aspect ratio, area and circularity of the cells. Consistent with our visual inspection, 
quantitative measurements revealed a near two-fold increase in the approximate 
length to width ratio (aspect ratio, 3.30 vs 1.77 vs 1.63) of SUMO2 KO cells as 
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compared to WT and SUMO1 KO cells, respectively. Additionally, we observed a 
decrease in the average cell area (1092µm2 vs 1705µm2 vs 1710µm2) and circularity 
(0.46 vs 0.63 vs 0.70) of the SUMO2 KO cells compared to WT and SUMO1 KO cells 
(Figure 11A). No significant differences were observed in the average aspect ratio or 
cell area between SUMO1 KO and WT cells, although SUMO1 KO cells were slightly 
more circular in comparison to WT cells (Figure 11A). Further assessment of the 
rescue cell lines confirmed that re-introducing SUMO2 rescued the morphology 
changes (Figure 11). In contrast, changes in morphology were not rescued in the 
S2KO+S1 cell line, indicating that SUMO1 overexpression cannot functionally 
compensate for the loss of SUMO2 (Figure 11). Collectively, these results reveal a 
unique and paralog-specific function for SUMO2 in regulating cell morphology.  
 
Cell Cycle Analysis of SUMO KO Cells 
 
Previous studies have shown that SUMO1 and SUMO2/3 have unique associations 
with mitotic chromosomes and that sumoylation of key mitotic regulators is required 
for timely cell cycle progression (23, 24, 32, 198-200, 241). We therefore used flow 
cytometry to gain insights into possible differences in the cell cycle dynamics of WT 
and SUMO KO cells. Using this approach, we found a nearly identical distribution of 
cells in the G0/G1, S and G2/M phases of the cell cycle in WT, SUMO1 and SUMO2 
KO cell lines (Figure 12A). Of interest, we detected a population of cells that had a 
greater than 2N DNA content specifically in the SUMO2 KO cells. Quantitative analysis 
revealed that this population of >2N cells was significantly higher in the SUMO2 KO 
cells as compared to WT, whereas no other significant differences between cell lines 
were identified (Figure 12B).  
 
 85 
Characterization of PML-NBs in SUMO KO Cells 
 
Sumoylation has important roles in regulating the assembly and function of 
promyelocytic leukemia nuclear bodies (PML-NBs) (9, 162, 242). In particular, 
sumoylation is thought to affect the phase separation of proteins that underlies the 
formation of these membraneless organelles (243) although the individual functions of 
SUMO1 and SUMO2 in this process are less clear. We therefore analyzed the number 
and size of PML-NBs in WT and SUMO KO cells using antibodies specific for PML 
and another resident PML-NB protein, DAXX, coupled with immunofluorescence 
microscopy. Consistent with non-redundant roles for the paralogs in PML-NB 
assembly and function, we observed a significant decrease in the number of nuclear 
bodies detected with both PML and DAXX in the SUMO1 and SUMO2 KO cells (Figure 
12C and D). In agreement with the literature (58) we observed a mean of 
approximately 13-14 PML-positive foci per nucleus in WT cells, with a reduction to 
approximately 6-7 in SUMO1 and SUMO2 KO cells per nucleus (Figure 12D). 
Moreover, although DAXX was only detected in a subset of PML-NBs, a similar 
decrease in DAXX-positive foci was observed in the KO cells as compared to WT. 
Specifically, an average of 4-5 DAXX-positive foci were detected per nucleus in WT 
cells, whereas only 1-2 foci were detected in SUMO1 KO cells and 0-1 per nucleus in 
SUMO2 KO cells. Surprisingly, the decrease in PML-positive foci in SUMO2 KO cells 
was not rescued by re-introducing SUMO2 expression, whereas the number of DAXX 
positive foci was partially restored (Figure 12D). These findings reveal non-redundant 
roles for SUMO1 and SUMO2 in affecting PML-NB assembly or integrity and suggest 
that loss of SUMO function may have irreversible effects on factors underlying their 
number and size. Further studies will be needed to determine whether the observed 
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decrease in NBs are due to lack of formation of PML-NBs, or if the stability is 
compromised in the absence of SUMO1 and SUMO2. 
 
Characterization of Cellular Stress Responses in SUMO KO Cells 
 
MTT Assay and Mitochondrial Function 
 
 
Sumoylation has important functions in regulating cellular stress responses, including 
DNA damage and replication stress, oxidative stress and protein misfolding caused by 
heat shock or other insults (244). To investigate the individual requirements for 
SUMO1 and SUMO2 in response to cellular stressors, we challenged WT, SUMO1 
KO and SUMO2 KO cells with a variety of stress conditions and measured cell survival 
using an MTT assay. The MTT assay provides a quantitative readout of cell viability 
and mitochondrial function, as the signal is dependent on mitochondrial respiration 
(245). We first validated the MTT assay for linearity and found that the readout is a 
linear function of cell number for WT and SUMO KO cells (Figure 13A). We also noted, 
however, that the MTT readout for the SUMO2 KO cells was consistently lower 
compared to WT and SUMO1 KO cells. Taking advantage of the SUMO2 rescue cell 
lines described above, we found that re-introduction of SUMO2 partially rescued the 
reduced MTT signal of SUMO2 KO cells, whereas overexpression of SUMO1 
increased the signal above WT values (Figure 13A). These findings suggest that 
SUMO1 and SUMO2 may have unique and non-redundant roles in regulating the 





Proteotoxic Stress Response 
 
 
To investigate the functions of SUMO1 and SUMO2 in response to proteotoxic stress, 
we treated cells with varying doses of two different drugs, Azetidine-2-carboxylic acid 
(AZC) and Eeyarestatin I. AZC is a proline amino acid analog that causes protein 
misfolding when incorporated into newly synthesized polypeptides (246). WT and 
SUMO KO cells were treated with varying doses of AZC for 72 hours and cell viability 
was measured using the MTT assay (Figure 13B). We observed a dose-dependent 
decline in WT cell viability, demonstrating drug toxicity, and similar dose-dependent 
declines were also observed in SUMO1 and SUMO2 KO cells. These findings suggest 
that the SUMO paralogs do not have an obvious effect on the response to protein 
misfolding caused by AZC, or that SUMO1 and SUMO2 are functionally redundant in 
this response.  
 
Eeyarestatin I (EerI) is an inhibitor of protein translocation into the endoplasmic 
reticulum (ER), in part through inhibition of Sec61 and the p97 AAA+ ATPase. It also 
inhibits ER-associated degradation (ERAD), which targets misfolded proteins in the 
ER for degradation through the ubiquitin proteasome pathway (182, 247). Treatment 
of cells with EerI leads to the accumulation of ubiquitylated proteins in the cytoplasm, 
but whether sumoylation also plays a role in the response to EerI has not been 
previously tested. WT and SUMO KO cells were therefore treated with varying doses 
of EerI for 48 hours and viability was measured using the MTT assay (Figure 13 C). 
SUMO2 KO cells were uniquely sensitive to EerI and sensitivity was most pronounced 
at 2 µM, where SUMO2 KO cell viability was reduced to 30%, compared to ~60% in 
WT and SUMO1 KO cells. To investigate whether sensitivity to EerI was due 
specifically to the loss of SUMO2, we performed dose-response assays using SUMO2 
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KO rescue cell lines. Surprisingly, re-introduction of SUMO2 and overexpression of 
SUMO1 both rescued the enhanced sensitivity of SUMO2 KO cells to EerI. Thus, 
differences in the relative expression levels of SUMO1 and SUMO2 may influence 
their roles in the cellular response to EerI. 
 
Genotoxic Stress Responses 
 
To study the functions of SUMO1 and SUMO2 in response to genotoxic stress, we 
investigated the sensitivity of WT and SUMO KO cells to treatment with hydroxyurea 
(HU), a drug that inhibits ribonucleotide reductase and causes DNA replication arrest 
and double-strand breaks (248). Cells were treated with varying doses of HU for 72 
hours and viability was measured using the MTT assay. This analysis revealed that 
SUMO1 and SUMO2 KO cells were similarly less sensitive to HU as compared to WT 
(Figure 13D). SUMO1 and SUMO2 KO cells showed equal resistance at doses of HU 
below 400µM, whereas SUMO2 KO cells exhibited slightly greater resistance at doses 
above 400µM. The reduced sensitivity of SUMO2 KO cells to HU was rescued by 
reintroducing SUMO2 but not by overexpressing SUMO1 (Figure 13D). These findings 
indicate that SUMO1 and SUMO2 have non-redundant functions in promoting cell 
survival in the presence of HU-induced DNA replication stress.  
 
Lastly, the reduced toxicity of HU may be due to mechanisms that limit its effect on 
nucleotide biosynthesis and DNA replication arrest, or on mechanisms that operate 
downstream of replication arrest. To distinguish between these possibilities, we 
assessed the effect of HU treatment on cell cycle progression by measuring cell growth 
over 4 days in the presence or absence of 700 µM HU (Figure 13E). Compared to 
untreated cells, which all exhibited exponential growth, all treated cells showed a near 
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complete inhibition of proliferation. Thus, WT and SUMO KO cells exhibited similar cell 
cycle arrests in response to HU treatment, consistent with expected inhibition of DNA 
replication. This indicates that the reduced sensitivity of SUMO KO cells to HU is due 
to effects downstream of replication arrest. 
 
Transcriptomics Profiling of SUMO KO Cells 
 
Hundreds of studies have examined the effects of SUMO-modified transcription 
factors and chromatin remodeling proteins on the expression of target or reporter 
genes, however there is limited data on the roles of the SUMO paralogs in regulating 
global gene expression (201, 216, 249). To address this gap in knowledge, we 
analyzed the effects of SUMO1 and SUMO2 knockout on the transcriptome of U2OS 
cells.  
 
Summary of Findings and Validation of Results 
 
Using RNA sequencing (RNA-seq), we identified a combined total of 10,336 genes 
that were differentially expressed in SUMO1 and SUMO2 KO cells as compared to 
WT (Figure 14 A). These differentially expressed genes (DEGs), account for a 
remarkable 70% of all identified genes. Of the identified DEGs, 42% (4,343 genes) 
were uniquely affected in SUMO2 KO cells and 20% (2,068 genes) were unique to the 
SUMO1 KO cells (Figure 14 A). Despite the differences in number of affected genes, 
nearly equal numbers of DEGs were up and down regulated in each cell line. 
Collectively, these findings are consistent with sumoylation playing a profound role in 
affecting gene expression and provide evidence that SUMO1 and SUMO2 perform 
unique and non-redundant functions that affect both activation and repression of 
different subsets of genes. 
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To help focus our analysis, we tightened the significance threshold to only include 
genes with a log2 fold-change ≥2 (equivalent to a 4-fold change). This more stringent 
parameter resulted in a combined total of 861 DEGs, and highlighted a more prominent 
role for SUMO2 in affecting gene expression, as 95% of these DEGs were unique to 
the SUMO2 KO cells (Figure 14 A). Consistently, many DEGs with the greatest fold 
changes in SUMO1 KO cells overlapped with SUMO2 KO cells (Figure 14B). 
 
To validate our RNA-seq findings, we selected a subset of up and down-regulated 
DEGs and tested gene expression by qRT-PCR. We found a strong correlation (R2 > 
0.9) between the assays for both SUMO KO cell lines (Supplemental Figure 5E). To 
further validate that the robust gene changes observed in SUMO2 KO cells were due 
specifically to the loss of SUMO2, we also analyzed gene expression levels in both of 
the SUMO2 KO rescue lines (S2KO+S2 and S2KO+S1) by qRT-PCR. We first used 
qRT-PCR to quantify SUMO1 and SUMO2 mRNA levels in all tested cell lines to 
confirm SUMO1 and SUMO2 re-expression in the rescue lines (Figure 14C). We then 
analyzed 16 DEGs and found that expressing SUMO2 in the SUMO2 KO (S2KO+S2) 
cells resulted in near-WT levels of gene expression. Interestingly, expression values 
in the S2KO+S2 cells often went beyond WT values and in the opposite direction of 
the SUMO2 KO cells (Figure 14D and E), suggesting that SUMO2 has a strong effect 
on the expression of these genes. Further in support of the observed gene expression 
changes resulting from a direct loss of SUMO2, we also found that gene expression 
values were not rescued when SUMO1 was overexpressed in SUMO2 KO cells 
(S2KO+S1) (Figure 14C-E). Moreover, gene expression levels from these cells were 
nearly indistinguishable from SUMO2 KO cells, demonstrating that SUMO1 is unable 






To identify possible patterns or clusters of genes affected by the loss of SUMO1 and 
SUMO2, we next mapped the KO cell DEGs from our RNA-seq analysis that had a 
>4-fold change in expression to the human genome (Figure 15A and B). SUMO1 KO 
DEGs were randomly scattered throughout the genome, with the exception of genes 
clustered near the end of chromosome 2 and a cluster of histone genes on 
chromosome 6. Notably, these and other more significantly affected DEGs in the 
SUMO1 KO cells were down-regulated, as represented by the larger blue dots on the 
karyoplot. In contrast, SUMO2 KO DEGs were more equally up and down-regulated. 
In addition, “hotspots” of up and down-regulated SUMO2 KO DEGs were observed 
throughout the genome, including the same histone gene cluster on chromosome 6 
that was observed in SUMO1 KO cells. Closer examination of these histone genes 
revealed opposing effects of SUMO1 and SUMO2, as they were down-regulated in 
the SUMO1 KO cells but up-regulated in the SUMO2 KO cells (Figure 15C). Lastly, 
we found that the SUMO2 KO DEGs often occurred at regions of high gene density, 
as represented by the gray density plot under each chromosome, whereas there was 
no such clear association with SUMO1 KO DEGs. Of note, DEGs identified in SUMO1 
and SUMO2 KO cells were equally distributed between positive and negative sense 
strands of the genome and among genes of varied lengths. 
 
Gene Set Enrichment Analysis 
 
 
To explore the cellular functions associated with genes affected by the loss of SUMO1 
or SUMO2, we turned to the Broad Institute’s Gene Set Enrichment Analysis (GSEA) 
(250). Significantly enriched gene sets were characterized into five broad categories: 
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nucleus-related, transcription and signaling, cellular stress response, immune 
response and cell morphology (Figure 16A). Intriguingly, although a majority of these 
gene sets were enriched in both the SUMO1 and SUMO2 KO cells, the same gene 
sets often contained genes with opposing expression levels. For instance, histone 
modification gene sets were heavily enriched with down-regulated genes in the 
SUMO1 KO cells (blue dots), and up-regulated genes in the SUMO2 KO cells (red 
dots). This is in-line with our previous observation that histone gene expression 
decreases in SUMO1 KO cells yet increases in SUMO2 KO cells, and further reveals 
that the paralogs can have opposing effects on gene expression.  
 
A similar trend of shared gene sets with opposing expression levels was also observed 
for the transcription and signaling, cellular stress response and immune response 
categories. The immune response categories were of particular interest in light of 
recent discoveries highlighting the importance of sumoylation in the immune response 
(164, 251, 252). Consistent with the literature, we found an enrichment in innate 
immune response gene sets, such as interferon (IFN) α and γ responses, interleukin-
signaling and viral genome integrity. A closer look at the data revealed that a majority 
of IFN-α response genes are up-regulated in the SUMO2 KO cells (Figure 16B). These 
same genes were also mostly up-regulated in the SUMO1 KO cells, but to a lesser 
extent (Figure 16B). Conversely, IFN-γ response genes are almost all down-regulated 
in the SUMO1 KO cells, but have mixed expression in the SUMO2 KO cells (Figure 
16B). Lastly, cell morphology-related gene sets were of interest because of the 
previously described cell morphology phenotype observed uniquely in the SUMO2 KO 
cells. Notably, individual gene sets in this category, including the extracellular matrix 
and epithelial to mesenchymal gene sets, were uniformly down-regulated in the 
SUMO2 KO cells (Figure 16). Taken together, these findings reveal that SUMO1 and 
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SUMO2 have unique and non-redundant roles in regulating a broad range of genes. 
Moreover, they reveal a dominant role for SUMO2 in regulating gene expression, and 





Vertebrates express five SUMO paralogs whose individual functions remain to be fully 
understood. In this study, we revealed evidence that the paralogs have unique and 
tissue specific functions through analysis of SUMO1 and SUMO2 KO cells, and 
analysis of gene expression data from human tissues. Systematic analysis of the KO 
cells revealed paralog-specific phenotypes, such as varying responses to cellular 
stress, unique gene expression patterns and non-redundant roles in nuclear body 
integrity, as summarized in Table 2. Moreover, we observed morphological changes 
that were unique to the SUMO2 KO cells. Re-expression of SUMO2 in the SUMO2 KO 
cells rescued the cellular morphology, gene expression, and response to genotoxic 
and proteotoxic stress phenotypes. In contrast, overexpression of SUMO1 in the 
SUMO2 KO cells did not rescue these phenotypes. This indicates that SUMO1 is 
unable to functionally compensate for SUMO2 in these processes, thereby revealing 
that the paralogs have unique and non-redundant cellular functions. This section 
provides some perspective regarding the molecular mechanisms behind the 
phenotypes described in this paper.  
 
First, it is possible that the observed changes in cellular morphology, gene expression, 
nuclear body integrity and responses to cellular stress are due to an upstream reaction 
to loss of the paralogs, and therefore may not be the direct result of loss of SUMO1 or 
SUMO2. For instance, it is possible that the gene expression changes in the SUMO2 
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KO cells are due to loss of SUMO2-modified transcription or chromatin remodeling 
factors, or they could also be the result of a global stress response due to the loss of 
SUMO2. Analysis of differentially expressed genes by RNA-sequencing identified an 
enrichment in some specific stress response pathways, notably related to DNA repair. 
However, the lack of differentially expressed heat shock proteins, ubiquitin-
proteasome pathway components, and other canonical stress-response genes 
suggests that loss of the individual paralogs does not elicit a generalized stress 
response. 
 
Moreover, the observed changes in cellular morphology, gene expression, nuclear 
body integrity and responses to cellular stress may also be interconnected. For 
instance, we observed defects in PML-NBs in both KO cell lines, which could affect 
downstream PML-NB regulated processes, such as genome maintenance, the stress 
response, DNA repair and transcription (58-67). Additionally, changes in transcription 
could offer a potential explanation for the observed SUMO2 KO cell morphology 
changes. In support of this, we observed changes in the transcription of a broad 
spectrum of genes in the SUMO2 KO cells that could contribute to changes in cell 
morphology. These include genes involved in the epithelial to mesenchymal transition 
(EMT), the extracellular matrix, integrin-cell surface interactions and genes coding for 
Wnt-family proteins. Notably, canonical EMT-related genes were predominantly down-
regulated in the SUMO2 KO cells, suggesting that SUMO2 may regulate a non-
canonical EMT-like process. Lastly, multiple studies have revealed that the SUMO 
paralogs modify intermediate filaments, microtubule associated proteins and actin 
regulatory proteins (175, 253). Collectively, since sumoylation regulates cytoskeletal 
proteins, signaling pathways and gene expression, the morphology changes observed 
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in the SUMO2 KO cells are likely the sum result of the effects of sumoylation at multiple 
levels, from genes to proteins.  
 
With regard to the observed changes in the global transcriptome of the KO cells, 
previous studies have enhanced our understanding of how sumoylation regulates 
gene expression. For instance, many studies have identified that SUMO1 or SUMO2/3 
modification of a specific transcription or chromatin remodeling factor alters its activity, 
localization, stability or binding partners (201, 207, 208, 211). Many of these studies 
also noted that SUMO modification of these factors was associated with a decrease 
in gene expression, which may be driven by sumoylation-mediated recruitment of co-
repressors or co-repressor complexes (218, 249). Conversely, other studies have 
found that sumoylation of a specific transcription factor or chromatin remodeling 
protein enhances gene expression, thereby indicating that the effects of sumoylation 
are likely context dependent and promoter specific (207, 208, 218). In line with this 
reasoning is a relatively new hypothesis which suggests that sumoylation aids in 
transcription factor binding-site selection (217). However, the effects of the SUMO1 
and SUMO2 paralogs on regulating global gene expression has yet to be reported, 
thus unique paralog-specific roles in transcription remain poorly understood. To that 
end, we uncovered three important findings about the paralog-specific roles of SUMO1 
and SUMO2 in transcription using RNA-seq. 
 
First, we identified uniquely altered genes in both of the KO cells, revealing that the 
SUMO1 and SUMO2 paralogs each have non-redundant roles in transcription. 
Consistent with a previous ChIP-Seq study, which reported nearly double the number 
of SUMO2 binding sites as compared to SUMO1 in proliferating human fibroblasts 
(202), we found almost twice as many uniquely altered genes in the SUMO2 KO cells 
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than in the SUMO1 KO cells. Furthermore, we identified nearly 15-times the number 
of unique genes with a four-fold change in expression in the SUMO2 KO cells as 
compared to the SUMO1 KO cells. The finding that genes with larger changes in 
expression levels occurred in the SUMO2 KO cells is consistent with the finding that 
SUMO2 can more potently inhibit transcription of the glucocorticoid receptor as 
compared to SUMO1 (215). Moreover, re-expressing SUMO2 in the SUMO2 KO cells 
rescued gene expression changes to WT-like levels. Conversely, overexpressing 
SUMO1 in the SUMO2 KO cells did not affect gene expression values, revealing that 
SUMO1 is unable to functionally compensate for SUMO2. Taken together, these 
findings indicate that although both SUMO paralogs have important and non-
redundant roles in regulating gene expression, SUMO2 has a broader role in this 
essential cellular process.  
 
Secondly, although sumoylation was once considered a repressive modification, we 
identified nearly equal numbers of up and down-regulated genes in the SUMO2 KO 
cells. In contrast, we identified nearly twice as many down-regulated genes in the 
SUMO 1 KO cells, but only for genes with a four-fold change in expression. Taken 
together, this data reveals that SUMO2 can function as either an activator or repressor, 
whereas SUMO1 may function more as an activator for the limited number of genes 
that it regulates.  
 
Finally, gene set enrichment analysis (GSEA) revealed that although a majority of 
gene sets were enriched in both the SUMO1 and SUMO2 KO cells, the same gene 
sets often contained genes with opposing expression levels. Specifically, among a 
majority of GSEA categories, we observed a clear trend of down-regulated genes in 
the SUMO1 KO cells and up-regulated genes in the SUMO2 KO cells. We were 
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interested in exploring this further, specifically for the histone and immune-response 
gene categories, as discussed below.   
 
As mentioned, we observed an increase in histone gene expression levels in the 
SUMO2 KO cells, and a corresponding decrease in the SUMO1 KO cells. Consistent 
with this finding, previous ChIP-seq analysis revealed that both SUMO1 and SUMO2 
bind to histone gene promoters (202). Moreover, histone gene expression levels 
significantly increase upon knockdown of the Ubc9 SUMO E2 conjugating enzyme or 
the SUMO E3 ligase, PIASY (202). Our findings reveal that this previously observed 
increase in histone gene levels may be due specifically to the loss of SUMO2 modified 
regulators. Histone gene expression is tightly controlled by the cell cycle, with an 
approximate 35-fold increase in expression occurring specifically during S-phase 
(254). The lack of a significant difference in S-phase distribution between the SUMO 
KO cells, as quantified by flow cytometry (Figure 12A and B), indicates that the 
observed changes are being driven by something other than the cell cycle. Another 
potential mechanism could involve SUMO1 and SUMO2 mediated recruitment of 
transcriptional activators or repressors to specific genomic loci (201, 218). 
Interestingly, histone genes are regulated by a complex of proteins that form at histone 
loci, called histone locus bodies (255). Given the observed defects in PML-NB integrity 
in both the SUMO1 and SUMO2 KO cells, it is possible that the paralogs may have 
unique yet conserved functions in regulating membrane-less organelles, such as PML-
NBs and histone locus bodies, however, further work is needed. 
 
Genes involved in immune response processes were also uniquely up-regulated in the 
SUMO2 KO cells and down-regulated in the SUMO1 KO cells. These findings are 
consistent with previous studies that have reported an increase in immune response 
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genes upon abrogation of global sumoylation (132, 251, 252). There is also evidence 
that sumoylation can regulate innate immunity by altering the production of type I IFNs 
upon viral activation (164, 256). With regard to the paralogs, it has been reported that 
the combined loss of SUMO2 and SUMO3 drives a potent type I interferon (IFN) 
response, indicating that SUMO2 and SUMO3, but not SUMO1, are redundant and 
potent negative regulators of the type I IFN response (132). Furthermore, genes 
involved in systemic lupus erythematosus, an autoimmune disease with a potential 
association of innate immune response processes in disease pathogenesis (131), 
were significantly upregulated and enriched in the SUMO2 KO cells. These findings 
have important public health implications, especially in light of a global sumoylation 
inhibitor, TAK-981, that is currently in four concurrent clinical trials. This SUMO E1 
inhibitor is being evaluated in the clinic for metastatic solid tumors, head and neck 
cancers and relapsed CD20-positive Non-Hodgkin Lymphoma, and for cancer patients 
who test positive for COVID-19 (140-143). The predicted success of this inhibitor is 
based, in part, on the finding that it increases the type I IFN response and thus helps 
the body attack the cancer through potential immune-activating and anti-tumor 
activities. The collective findings from our study and others suggest that selectively 
targeting SUMO2 and SUMO3 may be sufficient to illicit a type I IFN response. In 
summary, the SUMO paralogs have unique and non-redundant functions in regulating 
thousands of unique genes. More work is needed to understand the mechanism 
driving this regulation, and to better understand the specific contexts for SUMO 
activating and repressing functions. 
 
What paralog-specific attributes could help explain their unique and non-redundant 
functions in regulating gene expression, nuclear body integrity, cellular morphology 
and responses to cellular stress? Defining features are likely to include differences in 
 99 
the SUMO1 and SUMO2 SIM interaction domains that confer paralog-specific 
interactions (52, 53, 145, 257). For instance, lysine residues unique to the SUMO2 
SIM interaction domain are critical for the intrinsic ability of SUMO2 to function as a 
strong transcriptional repressor, relative to SUMO1 (54, 178, 215). This repressive 
ability is attributed, in part, to SUMO2/3 specific binding and localization of 
transcriptional repressors and repressive complexes to promoters, which is mediated 
through SIM interactions (207, 218). Non-covalent paralog-specific interactions also 
mediate, in part, the cellular stress response and nuclear body integrity, thus 
differences in SUMO-SIM interactions could help explain other observed phenotypes 
of SUMO1 and SUMO2 KO cells as well (188, 258).  
 
Moreover, the ability of SUMO2/3 to efficiently form polymeric-SUMO2/3 chains 
represents a major difference from SUMO1, which is preferentially conjugated to 
substrates as a monomer. Polymeric-SUMO2/3 chains can act as either a degradation 
signal, or function to stabilize protein complexes (10, 180). Under conditions of stress, 
polymeric-SUMO2/3 chains are quickly and reversibly formed on target proteins 
involved in stress response pathways, such as heat shock proteins, apoptotic factors 
and DNA repair proteins (40, 69, 178). These target proteins are likely recruited to 
sites of stress-induced damage, such as DNA double strand breaks or mis-targeted 
proteins, in a SUMO-dependent manner. Intriguingly, we report that in the absence of 
SUMO1 and SUMO2, cells are more resistant to genotoxic stress than WT cells. This 
suggests non-redundant roles for the paralogs in the repair of DNA double strand 
breaks, potentially through paralog-specific spatiotemporal regulation of repair factors. 
One hypothesis is that monomeric SUMO1 modification may occur upstream of 
SUMO2/3 modification, and function to recruit repair factors to sites of damage, as 
observed by the SUMO1 modification of DNA repair protein FEN1 (259). This could 
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subsequently be followed by polymeric-SUMO2/3 modification, which through the 
activity of SUMO targeted ubiquitin ligases, such as RNF4, function to turn over repair 
factors, as observed for PCNA (10, 69, 260). Given that thousands of proteins are 
affected by the loss of SUMO1 and SUMO2, the mechanisms behind this observation 
are likely to be complex and require further exploration (19). Of note, such future 
studies would be enhanced by SUMO1 rescue cells, however our efforts to generate 
them thus far have not been successful, possibly due to toxic effects of SUMO1 
misregulation (116).   
 
Whether the observed phenotypes are a direct or indirect response to loss of the 
SUMO paralogs, or due to cross-talk between biological processes, our data indicate 
that the paralogs have unique and non-redundant roles in many cellular functions. An 
important next step will be to explore molecular mechanisms underlying paralog-
specific changes by going back into WT cells. More specifically, what are the effects 
of SUMO2 on the cytoskeleton and regulatory pathways that control cell morphology? 
How do SUMO1 and SUMO2 individually sensitize cells to treatment with 
hydroxyurea? What are the targets and consequences of SUMO1 and SUMO2 
modification on proteins localized to PML-NBs? Do SUMO1 and SUMO2 mediate 
association of transcription factors with unique regulatory proteins at gene promoters?  
 
Ultimately, it will also be important to explore the unique functions of SUMO paralogs 
in various tissues. Our gene expression analysis revealed that relative SUMO paralog 
expression levels are similar across hundreds of cell lines, regardless of tissue source, 
which is in contrast to varying paralog levels across normal human tissues. For 
instance, average SUMO2 expression levels are consistently higher than SUMO1 
levels across all analyzed cell lines from multiple tissue sources, including the liver. 
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However, in normal human tissues, SUMO1 expression is higher than SUMO2 in the 
liver and nine other organs. This suggests that the cellular environment strongly 
influences SUMO paralog expression, with cells in culture potentially adapting SUMO 
paralog expression levels optimized for growth conditions in 2-D culture. This 
highlights the importance of using the appropriate system to study functions of 
sumoylation. While basic information about the paralogs can be inferred using cell 
culture, as scientists have been doing for years and as we demonstrated in this study, 
the roles of the paralogs in specific tissues will likely need to be studied within an 
organism. For instance, diverse expression patterns of SUMO pathway genes in the 
mouse retina and in human placental tissues have been identified and used to define 
biologically significant roles for the SUMO paralogs in these tissues (154, 237).  
 
Lastly, SUMO3 expression levels were higher in a majority of normal human tissues 
than SUMO1 and SUMO2. This was an unexpected finding, based on the absence of 
any obvious phenotypes in SUMO3 KO mice, and the apparent low levels of SUMO3-
modified proteins in cell culture (Figure 9) (155). However, an observed increase in 
SUMO3 expression levels in adult mice as compared to young mice suggests that 
SUMO3 is important in post-developmental processes (155). Given the high degree of 
sequence and structural similarities between SUMO2 and SUMO3, this observation is 
certainly interesting and reveals that the functional contributions of SUMO3 are worth 
further exploration. In summary, we have provided evidence that SUMO1 and SUMO2 
have unique roles in regulating cellular morphology, nuclear body integrity, response 
to various cellular stressors and global gene expression. Our work provides a 
foundation for future medical and scientific SUMO-focused endeavors aimed at 
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Materials and Methods 
 
 
Human Cell Line and Tissue Expression Analysis 
 
Normalized gene RPKM values from 528 cancer cell lines were downloaded from The 
Broad Institute Cancer Cell Line Encyclopedia (CCLE) using the 02-JAN-2019 release 
(239). Student’s t-tests were used for pairwise comparisons and p-values are listed in 
the legend of Figure 8. Normal human tissue data were downloaded as normalized 
gene transcript per million (TPM) values from the Genotype-Tissue Expression (GTEx) 
Project Version 8, which is supported by the Common Fund of the Office of the 
Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, 
and NINDS. The number of samples available for each tissue are labeled in the figure. 
Heatmaps were made in Rstudio, using ggplot2 and the gganatogram package (261). 
 
CRISPR-Cas9 Genetic Knockout and Sequencing Validation 
 
Gene specific knockout of SUMO1 and SUMO2 in U2OS cells using CRISPR-Cas9 
was performed according to a previously published protocol (262). In brief, single guide 
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RNA (sgRNA) was designed by the CRISPR design tool (http://crispr.mit.edu) as 
following: SUMO1 5’-TCCCTCCTCCCTGCGCGAAG-3’;SUMO2 5’-
CCTCACCTGTCGTTCACAAT-3’. sgRNA was cloned into pSpCas9(BB)-2A-GFP 
vector using BpiI enzyme sites (Thermo Scientific), and the vector was transiently 
transfected into U2OS cells using X-tremeGENE HP reagent (Roche) according to 
manufacturer's protocol. Transfected cells expressing GFP were sorted as single cells 
into 96-well plates by FACS at The Bloomberg Flow Cytometry and Immunology core. 
CRISPR-Cas9 introduced mutations were identified using the Clonetech Guide-it Indel 
Identification Kit (Clonetech Catalog Number: 631444), following the user manual. 
Genomic primer sequences for SUMO1 and SUMO2 are listed in Table 4, with 
Clonetech regions of homology indicated. Ten individual SUMO1 and SUMO2 
colonies were sent for Sanger DNA sequencing at the Johns Hopkins University 
Genetic Resources Core Facility. Aligned sequence reads surrounding the mutation 
sites are in Supplemental Figure 2 and 3. U2OS WT, SUMO1 KO and SUMO2 KO 
cells were confirmed free of mycoplasma contamination using the Promokline PCR 
Mycoplasma Test Kit I/C (Part Number: PK-CA91-1024) following the vendor protocol.  
 
Cell Lines and Cell Culture Conditions 
 
 U2OS WT, SUMO1 KO, SUMO2 KO, SUMO2KO+SUMO2 and SUMO2KO+SUMO1 
cells were grown at 370C, 5% CO2 in Gibco DMEM (PN: 11965-092) supplemented 





Generation of Stable Rescue Cell Lines 
 
pTWIST CMV Puro plasmids encoding precursor SUMO1 or SUMO2 expression were 
purchased from TWIST Biosciences (Supplemental Figure 4). 2x105 SUMO2 KO cells 
grown overnight were transfected with 1ug of pTWIST plasmids using Lipofectamine 
2000, following their standard protocol (Invitrogen Lot no. 1881535). Fresh Gibco 
DMEM medium with 10% FBS was supplied after 6 hours of incubation. Puromycin 
(Sigma Cat No: P8833) selection was performed 48 hours post-transfection at a final 
concentration of 2ng/mL for 4-5 days. Stable rescue cell lines were obtained by single-
cell cloning and maintained in 1ng/mL puromycin-containing DMEM medium for a 
month, and then grown in standard conditions, per above. SUMO paralog expression 
levels in the rescue cell lines were validated by immunofluorescence microscopy and 
immunoblotting with corresponding antibodies, per Table 5.  
 
Immunoblotting and Semi-Quantification of SUMO Levels  
Cells were lysed with 2x Laemmli Buffer (4% SDS, 20% glycerol, 125mM Tris-Cl 
pH6.8, 10% 2-mercaptoethanol, 0.02% bromophenol blue) and denatured at 95°C for 
5 minutes. 10µL of whole cell lysate was loaded onto 10% SDS-polyacrylamide gels, 
run at 120V for 2 hours in a Biorad Mini-Protean vertical electrophoresis chamber, and 
transferred onto PVDF membrane in a Biorad Mini Trans-Blot cell at 100V, 4°C for 2 
hours. Membrane was briefly washed with 1xTBS and blocked in 5% milk (in 1xTBS) 
for 1 hour at room temperature with gentle shaking. Membranes were incubated with 
anti-SUMO primary antibodies (SUMO1: [1:1000]; SUMO2: [1:800]; Tubulin: 
[1:10,000]) overnight at 4°C, washed 3x10 minutes with 1xTBS-T, incubated with HRP 
conjugated secondary antibodies ([1:10,000]) in 5% milk for 1 hour at room 
temperature, followed by washing for 3x10 minutes with 1xTBS-T. Membranes were 
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activated using Amersham ECL prime western blotting detection reagent (Cat No. 45-
002-401) and exposed using a medical film processor (Konica Minolta Medical & 
Graphic Inc. Model: SRX-101A).  
Developed films were scanned and imported into FIJI image processing software for 
semi-quantitative measurements of relative SUMO paralog expression (240). Images 
were converted into grayscale and SUMO signal intensities were measured using 
methods described by https://lukemiller.org/index.php/2010/11/analyzing-gels-and-
western-blots-with-image-j/. SUMO signal densities were normalized to corresponding 
tubulin loading controls and calculated by dividing knockout and rescues cell values 
by WT values. Graphs were created using Prism software. 
 
Immunofluorescence Microscopy and Quantitative Cellular Morphology 
Analysis 
 
For SUMO immunofluorescence staining and SUMO+tubulin co-staining, cells were 
seeded at 2.0x105 cells/coverslip in a 6-well dish and grown overnight. Harvest and 
staining of the cells were performed at room temperature as follows: cells were washed 
with 1xPBS and fixed in 4% paraformaldehyde for 20 minutes, followed by 
permeabilization in 0.05% Triton-X-100 (in 1xPBS) for 20 minutes. Cells were then 
incubated with anti-SUMO and anti-tubulin primary antibodies (Table 5) for 1 hour in a 
humidity chamber, washed in 1x PBS-T, and incubated with Alexa fluorescent 
secondary antibodies (Table 5) for 40 minutes. Coverslips were then mounted using 
Fluoroshield Mounting Medium with DAPI (Abcam, ab104139). Microscopy images 
were taken using an upright Zeiss Observer Z1 fluorescence microscope with an 
Apotome VH optical section grid. Non-saturated representative images showing 
 106 
SUMO protein levels and morphology of each cell line were taken using a 40x objective 
and exported as tif files from the AxioVision Release 4.8 software.  
 
Quantitative analysis of cellular morphology was performed as above, except cells 
were seeded at 1.8x105 cells/coverslip in a 6-well dish. Quantitative measurements 
were done in FIJI software (240) by manually outlining individual cells. Cellular aspect 
ratio, area and circularity were measured using built-in measurement functions in the 
FIJI analyze menu, and images were calibrated into microns before measuring. For 
each cell line, at least 800 cells from 3 independent experiments were measured and 
data were imported into Prism software for statistical analysis. The Kruskal-Wallis non-
parametric test was used for statistical comparison and calculation of p-values. 




4.5x106 cells were fixed in ice cold 70% EtOH and stained with Propidium Iodide in 
triplicate, following a standard protocol (263). Cells were analyzed using a BD LSRII 
flow cytometer at the JHU Flow Core. BD FACSDiva acquisition software was used to 
acquire 5.0x104 single events per sample, and G0 cells were centered on 100. FloJo 
version 10.6.1 was used for analysis. Statistics were calculated using an ANOVA and 
p-values are labeled on the final plots, made using ggplot in RStudio (261).  
 
Quantitative Nuclear Body Imaging and Analysis 
 
Cells were seeded at 2.5x105 cells/coverslip in a 6-well dish and grown overnight. Cells 
were rinsed in room temperature (RT) 1x DPBS (Gibco PN: 14190-144), fixed in 3.5% 
 107 
paraformaldehyde for 7 minutes at RT, permed in 0.05% Triton-X-100, for 20 minutes 
at RT and incubated for 1 hour in a RT humidity chamber with primary antibodies Table 
5. Cells were washed in 1x PBS-T, and incubated for 35 minutes in a RT humidity 
chamber with secondary antibodies (Table 5). Microscopy images were taken using 
an upright Zeiss Observer Z1 fluorescence microscope with an Apotome VH optical 
section grid. Non-saturated 16-bit gray images were exported from the AxioVision 
Release 4.8 software and opened in FIJI (240). Nuclei (DAPI) and foci (dsRED and/or 
GFP) signal thresholds were set using the RenyiEntropy algorithm and the Speckle 
Inspector function of the Biovoxxel plug-in was used to quantitate (264, 265): the 
number of foci per nuclei, foci signal intensity and foci perimeters. Non-parametric 
Wilcoxin test was used to calculate p-values in R and graphs were generated using 
ggplot2.  
 
Cellular Viability Analysis 
 
2 x 103 cells per well were plated into 96-well plates in 100µL of media and grown 
overnight. Each cell line was seeded in triplicate for each dose of the drug treatment. 
After treatment, each well was washed once with 1x DPBS, and then 100 µL of DMEM 
(without phenol red, Gibco 21063-029) containing 10% FBS and 10 µL of 12mM MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) were added to each 
well, including a negative control of 10 μL of the MTT solution added to 100 μL of 
medium alone. After 4 hours of incubation at 37°C with 5% CO2, 80 µL of the media 
was removed from each well, and 50 µL of DMSO was added to solubilize the 
metabolized insoluble formazan product. After incubation at 37°C for 10 minutes, 96-
well plates were analyzed using a plate reader (BioTek Synergy HT) and Gen5 
microplate software (2.00.17) at an absorbance of 540 nm. For the analysis, the 
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negative control signal was deducted from all wells, before relative cell viability was 
calculated for each treated group as a percentage of the untreated group for each cell 
line. Reagent information is in Table 3. 
 
Transcriptome Analysis and Data Visualization 
 
Three biological replicates of each authenticated and validated U2OS parental, 
SUMO1 KO and SUMO2 KO cell lines were sent to Novogene Co., Ltd for total RNA 
isolation, QC and library preparation. Transcriptomic data for the three cell lines with 
three biological replicates were generated using an Illumina HiSeq 4000 sequencer. 
Paired-end reads were obtained with a read depth of over 60 million reads per sample. 
The reads were cleaned and mapped to the reference genome using STAR, HTseq, 
Cufflink and Tophat programs. This resulted in a total of 48,162 Ensembl reads. Of 
those, 23,758 were mapped to Entrez gene IDs and used in downstream analysis. 
Genes were filtered to keep those that had approximately 10 or more read counts in 
at least all three replicates of one cell type, which resulted in a total of 14,999 genes 
for downstream analysis (266). Reads were evenly distributed throughout the genome 
and both a multidimensional scaling (MDS) plot and calculated Pearson correlations 
among replicates demonstrated highly consistent read counts with minimal variance 
between biological replicates (Supplemental Figure 5).   
 
The Rstudio Karyoplotter package was used to visualize mapped DEGs along human 
chromosomes (267). Pathway enrichment analysis using GSEA (version 4.0.3) from 
the Broad Institute and visualization of the data using Cytoscape and EnrichmentMap 
were performed following published protocols (250, 268). The GSEA algorithm 
calculates GO enrichments from a list of global gene expression values, not just those 
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that meet a specific threshold criteria. Specifically, GSEA used the expression values 
of the same 14,999 genes from the SUMO1 and SUMO2 KO cells to generate two 
ranked lists of genes (one for each KO cell as compared to WT), which were then 
tested for gene set enrichments. For the analysis, .gct data of FPKM values for all 3 
replicates for all 3 samples, and a phenotypes .cls file were loaded into GSEA. 1000 
permutations were used, collapsed to match the Human NCBI Entrez GENE ID 
MSigDBv.7.1.chip platform, otherwise default settings were used. Results were 
compiled and analyzed in RStudio using GeneEnricher. Cytoscape (version 3.8.0 
using Java 11.0.6) was used to visualize Interferon and collagen gene sets.   
 
qRT-PCR for DEG Validation and Rescue Experiments  
 
Cells were seeded at 5.0×105 cells/well in 3.5mm dishes and grown overnight. Total 
RNA was extracted using the Sigma GenElute Mammalian MiniPrep kit (Sigma PN: 
RTN70) following the vendor’s protocol. Extracted RNA was analyzed by nanodrop for 
concentration and purity. cDNA was generated using the New England BioLab 
ProtoScript First Strand cDNA Synthesis Kit (NEB PN: E6300S) with 250ng of RNA 
and following the vendors protocol. Poly-d(T)23 VN primers were used to generate 
cDNA for all genes except for histone genes, for which we used random-hexamer 
primers which were also included in the NEB kit. We used random hexamer primers 
since histone genes do not contain polyA tails, and we wanted to properly verify our 
RNA-seq findings. The qPCR reaction was performed using Applied Biosystems 
PowerUp SYBR green master mix (PN: A25742) following the vendors recommended 
protocol. qPCR runs were performed using Applied Biosystems Quant Studio with 
Quant Studio v1.3.1 software. Gene expression was calculated from three biological 
 110 
replicates, each run in triplicate, using the Ct method and GAPDH as a validated 








Figure 8. SUMO paralog expression levels vary among human cell lines and tissues. A) 
SUMO paralog expression from 467 human cancer cell lines derived from 6 different tissues. 
Significant P-values (<0.05) were determined using a Students t-test, where: * = 0.027;                        
** = 2.8e-6; *** <1.6e-14. B) SUMO paralog expression from 61 human bone cancer cell lines. 
Individual P-values were calculated using a Students t-test and are labeled. The inlay data is 
specifically from U2OS cells, no statistics are reported since expression values come from one 
cell line. Data in A and B come from CCLE and are reported as -log10 transformed RPKM 
values. C) Anatomical heat maps of SUMO1-4 mRNA expression (Transcripts per Million 
(TPM)) in normal human tissue data from GTEx. D) A detailed heatmap of SUMO1-3 
expression in normal human tissues, ordered generally from the head down. The number of 





Figure 9. Generation of SUMO1 and SUMO2 KO cell lines. A) Schematic of CRISPR-Cas9 
strategy and sanger sequencing results. B) SUMO1-4 mRNA expression values in WT and KO 
cells, measured by RNA-sequencing. C) Representative western blots of WT and KO whole 
cell lysates show significant reduction in SUMO1 and SUMO2/3 conjugated proteins in 
respective KO cells. Tubulin is used as a loading control. D) Immunofluorescence microscopy 
images show loss of SUMO1 or SUMO2/3 specific signal in WT and respective KO cells. Cells 




Figure 10. SUMO2 has a unique role in regulating cellular morphology. A) Percentage of 
fibroblast-like cells counted from >2400 cells from three independent experiments as analyzed 
by immunofluorescence microscopy. B) SUMO2 re-introduction in S2KO+S2 cells, and 
SUMO1 overexpression in S2KO+S1 cells were validated by immunoblotting using antibodies 
specific for SUMO2/3 or SUMO1. Tubulin was used as a loading control. C) Expression levels 
of SUMO2/3 and SUMO1 (green) were assessed by immunofluorescence microscopy use 
specific antibodies and DAPI (blue) counterstaining. D) Morphology was analyzed by anti-





Figure 11. Rescue of S2KO Cells Reveals SUMO-specific role in cellular morphology. A) 
Quantitative shape analysis revealed changes in the average cellular aspect ratio, area and 
circularity in indicated cell lines. Over 200 cells from three independent experiments were 
analyzed for each cell line. Error bars represent standard deviation. P values were calculated 
by a Kruskal-Wallis test using where: **** p= 0.0001, *** p = 0.001, * p = 0.05, ns =p>0.05. B). 






Figure 12. Cell cycle and nuclear body regulation in SUMO KO cells. A) Representative 
overlay of flow cytometry histograms from WT, S1KO and S2KO cells. B) Quantitation of the 
percentage of cells in G0/G1, S, G2/M and >G2 cell cycle stages. P-values, labeled, were 
calculated using an ANOVA. C) Representative immunofluorescence microscopy images using 
antibodies specific for PML and DAXX. A merged image with PML in teal and DAXX in magenta 
is shown in the third panel. A zoomed-in view of a merged cell (outlined) is shown in the final 
panel. D) Quantitation of PML nuclear bodies, DAXX foci and PML NB perimeter size estimates 
are shown for each cell type. The number of cells analyzed per cell line was between 174-195. 
P-values for each cell line as compared to WT were calculated using an unpaired Wilcoxon 





Figure 13. SUMO paralogs have non-redundant functions in response to cellular stress. 
A) Baseline MTT assay of cells at various confluency. Simple linear regressions were 
calculated for each cell line and slopes for each regression were compared, with the R2 
reported as 0.91 (WT), 0.96 (S1 KO), 0.94 (S2KO), 0.81 (S2KO+S2), and 0.96 (S2KO+S1). 
B,C,D) Cell viability measurements. Cells were treated with indicated doses of B) AZC for 72 
hours, C) Eeyarestatin I for 48 hours, and D) HU for 72 hours followed by MTT assays. Relative 
cell viability is calculated as the fraction of MTT signal at each dose of the drug compared to 
untreated control cells. E) Cell growth analysis. Cells were treated with 700μM HU (dash line) 
or without HU (solid line) for up to 4 days. Viable cells were counted at each time point and 





Figure 14. Overview of RNA-sequencing results of SUMO KO cells. A) Venn Diagram 
showing the numbers of unique and overlapping up and down-regulated differentially 
expressed genes (DEGs) in the SUMO1 KO and SUMO2 KO cells, at two significance 
thresholds: False Discovery Rate (FDR) <0.05 and FDR < 0.05 + Log2 fold change (FC). B) 
Volcano plots of unique and overlapping SUMO1 and SUMO2 KO cell DEGs. The horizontal 
dashed line represents FDR <0.05 and the vertical dashed lines represent Log2 fold change 
values of -2 and +2. C) Validation of SUMO1 and SUMO2 gene expression values by qRT-
PCR in WT, KO and rescue cell lines. D) Representative bar plots of Log2FC expression values 
of up and down-regulated genes, tested by qRT-PCR. E) Heatmap summarizing SUMO2 KO 




Figure 15. Karyoplot of SUMO KO cell DEGs and histone genes. A and B)The genomic 
locations of up and down-regulated genes in A) SUMO1 KO cells and B) SUMO2 KO cells. 
DEGs are represented by red and blue dots, respectively. The size of the dots corresponds to 
significance, with a bigger dot representing a more significant change in gene expression. The 
gray plot below each chromosome represents gene density at each loci. Percent of DEGs per 
chromosome is labeled to the right of each chromosome (# of DEGs on the chromosome / total 
# of DEGs) x 100. The major histone gene locus on chromosome 6 is highlighted. C) A heatmap 





Figure 16. Gene Set Enrichment and Cytoscape Analysis of SUMO KO cells. A) Enriched 
gene sets for SUMO1 KO and SUMO2 KO cell DEGs. The color of the dot corresponds to the 
GSEA normalized enrichment score (NES), which quantitatively represents the contribution of 
down-regulated (blue) and up-regulated (red) genes to each gene set. The size of the dot 
corresponds to the significance, with a bigger dot representing a more significant enrichment. 












Table 3. Reagents used for stress assays. 
Reagent Vendor Part Number Solvent  
Eeyarestatin I EMD Millipore 324521-25MG DMSO 
Hydroxyurea Amresco 1B1368-25G PBS 
L-Azetidine-2-
carboxylic acid 
Sigma A0760-50MG PBS 








Table 5. Antibodies and dilutions used in SUMO KO studies. 








SUMO1 (IF & WB) [1:1000] Mouse 














Santa Cruz SC-966 PG-M3 PML (IF) [1:100] Mouse 
Atlas HPA008736 DAXX (IF) [1:500] Rabbit 
Invitrogen A11001 Mouse – 488 (IF) [1:400] Goat 
Invitrogen 35561 Rabbit – 594 (IF) [1:400] Goat 
Jackson Lab 115-035-003 Mouse – HRP (WB) [1:10,000] Goat 
Jackson Lab 111-035-144 Rabbit – HRP (WB) [1:10,000] Goat 










Supplemental Figure 1. SUMO4 gene expression is low in normal human tissues. SUMO4 
gene expression values from GTEx, reported as transcripts per million (TPM). Note the scale, 






Supplemental Figure 2. SUMO1 KO cell CRISPR mutations. The SUMO1 loci in U2OS WT 
cells is on top, with the two SUMO alleles from the SUMO1 KO cells aligned below. SUMO1 
sgRNA is highlighted in red text and the SUMO1 start codon is highlighted in green text. The 
start codon is deleted in both alleles, resulting in different mutations and therefore 




Supplemental Figure 3. SUMO2 KO cell CRISPR mutations. The SUMO2 loci in U2OS WT 
cells is on top, with the SUMO2 alleles in the S2KO cells aligned below. SUMO2 sgRNA is 
highlighted in red text. Stop codons are prematurely created in each allele, as highlighted in 




Supplemental Figure 4. Precursor SUMO1 and SUMO2 sequences for rescue cell lines. 
SUMO1 and SUMO2 gene sequences, and translated amino acid sequences are shown. Di-
glycine motifs, required for SUMO activation, are highlighted in red. 
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Supplemental Figure 5. Processing of SUMO KO cell RNA-seq data. A) An MDS plot 
showing tight clustering of replicates, and differences between cell lines. B) Pre- and post-
filtering plots based on low number of reads. C) Plots showing pre- and post-TMM 
normalization. Library sizes were relatively similar. D) Correlation plot of SUMO1 KO log2FC 
values as compared to SUMO2 KO log2FC values. The low correlation suggests that the noise 
in our samples are low, and thus the large differences in DEG numbers observed between the 
SUMO1 KO and SUMO2 KO cells represent a true biological difference. E) Correlation plot of 
gene expression data from qRT-PCR as compared to RNA-seq. The correlation (R2>0.9) 
reveals that results obtained from both methods are similar and therefore that RNA-sequencing 




Supplemental Figure 6. Individual bar plots of SUMO KO cell DEGs assayed by qRT-
PCR. Bar plots of log2FC gene expression values as measured by qRT-PCR. Genes are 
grouped by their cellular function categories. For reference, log2FC gene expression values 








Chapter 4: A Cellular and Bioinformatics Analysis of 





This chapter was published in The Journal of Gastrointestinal Oncology 
(2019, Oct 25;10(5): 821-830) and is reproduced here with copyright 
permission from the AME Publishing Company. 
 
Article DOI: 10.21037/jgo.2019.05.09 
 
 













Sumoylation is an important post-translational modification that involves the 
conjugation of the Small Ubiquitin-related Modifier (SUMO) onto target proteins. This 
modification is reversed through the catalytic activity of SUMO isopeptidases, known 
as SENPs. One of these SENPs, SENP1, was reported to be overexpressed in human 
pancreatic cancer cells and patient tissues. Since elevated SENP1 expression levels 
can be used as a prognostic marker for a subset of cancers, we set out to further 
explore the overexpression of SENP1 in pancreatic cancer. We found that SENP1 
protein levels were not significantly different between pancreatic cancer and normal 
pancreas-derived cell lines. To evaluate SENP1 expression in patient samples, we 
analyzed large publicly available datasets and found that SENP1 mRNA levels were 
significantly lower in pancreatic cancer tissue as compared to normal pancreas tissue 
samples. Furthermore, we found that the SENP1 gene is amplified in less than 1% of 
sequenced pancreatic cancer patient samples and that expression levels have no 
association with patient survival. Based on our analysis, we conclude that SENP1 is 
not overexpressed in pancreatic cancer and is therefore not likely to be an effective 
biomarker for this disease. Through this work, we also outline a simple but powerful 
bioinformatics workflow for the assessment of mRNA expression levels, genomic 











The Small Ubiquitin-related Modifier (SUMO) is a well conserved 110 amino acid 
protein that is post-translationally conjugated onto target proteins in a dynamic and 
reversible process called sumoylation. SUMO is covalently attached to target proteins 
through an E1, E2 and E3 enzymatic cascade. Deconjugation of SUMO from target 
proteins is catalyzed by sentrin-specific isopeptidases, or SENPs (22, 269). A wide 
range of essential cellular functions are regulated by sumoylation, such as 
transcription, chromatin remodeling, DNA replication and cell division, among many 
others (76, 77). Many of these essential cellular processes are misregulated in human 
cancers (75). As such, misregulation of SUMO conjugating and deconjugating 
enzymes have been implicated as contributing factors in the development and 
progression of many cancers (197, 270-273). Consequently, individual pathway 
components have become attractive drug targets and potential biomarkers for cancer 
therapies (104, 274, 275). For instance, an inhibitor of the SUMO E1 conjugating 
enzyme has been shown to inhibit sumoylation globally and thereby decrease cancer 
cell proliferation and viability (64).  
 
Our lab and others have identified unique roles of the SUMO isopeptidase, SENP1, in 
regulating genes important for cancer-related processes, such as chromosome 
segregation (24, 200) and cellular proliferation (103, 108, 110, 276). Through 
misregulation of SENP1 expression, these genes and processes can become 
misregulated and contribute to cancer development and progression. As such, it has 
been demonstrated that SENP1 expression levels can be used as a prognostic marker 
for a molecularly defined subset of prostate cancers (277). These promising findings 
prompted us to further explore reported SENP1 overexpression in pancreatic cancer 
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(112), a lethal disease that is projected to become the second leading cause of cancer-
related deaths in both men and women by 2030 (278). Lack of effective treatment 
options render this disease particularly lethal and early diagnosis of the disease is 
essential in order to optimize treatment effectiveness and patient survival (279). The 
previous observation that SENP1 is up-regulated in pancreatic cancer raised the 
intriguing possibility that SUMO inhibitors could be used as an effective treatment 
option for this disease. We therefore chose to further characterize and validate SENP1 
expression levels in pancreatic cancer cells and patient tissues as a step toward 
further establishing SENP1 as a biomarker for treatment of pancreatic cancer with a 
SUMO inhibitor.  
 
We found using cell-based assays and analyses of large-scale sequencing studies 
from pancreatic cancer patients that in contrast to a previous report (112), SENP1 is 
not significantly overexpressed in pancreatic cancer. Through this work, we also 
provide the field with a powerful bioinformatics workflow that can be used by 
researchers to evaluate expression levels and genomic alterations of putative 





Characterizing SENP1 Expression and Localization in Human Cell Lines 
 
To evaluate SENP1 expression in pancreatic cancer, we first looked at SENP1 
messenger RNA (mRNA) and protein levels in six human cell lines. We used the HPNE 
cell line, which is derived from non-cancerous pancreas tissue (280), for comparison 
to the pancreatic cancer cell lines AsPC-1, BxPC-3, CFPAC-1 and PANC-1, and to 
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the cervical cancer cell line, HeLa. We found using qRT-PCR that the HPNE cells had 
significantly lower relative SENP1 mRNA expression as compared to all other tested 
cell lines (p-values < 0.05) (Figure 17A). Consistent with previous findings, the AsPC-
1, BxPC-3 and CFPAC-1 cells had indistinguishable differences in SENP1 expression, 
whereas the PANC-1 cell line had the highest levels of SENP1 expression (112). 
 
To explore whether the elevated SENP1 mRNA levels in PANC-1 cells were 
associated with a gene duplication event, we turned to the Broad Institute’s Cancer 
Cell Line Encyclopedia (CCLE, portals.broadinstitute.org/ccle) (239). We found that 
there were two copies of SENP1 in all four of our tested pancreatic cancer cell lines 
(Figure 17B), indicating that the elevated SENP1 mRNA levels in PANC-1 were not 
associated with a SENP1 gene duplication event. Consistent with our findings, RNA 
sequencing data from CCLE also showed a similar pattern of SENP1 mRNA 
expression for the tested pancreatic cancer cell lines.  
 
To investigate the relationship between mRNA and protein expression levels, we 
probed whole cell lysates from our six human cell lines using a validated SENP1 
antibody. We found that in contrast to our qPCR results, there were no significant 
differences in SENP1 protein levels between the tested cell lines (Figure 17C and 1D). 
Specifically, SENP1 protein levels were not as elevated in the PANC-1 cells as were 
expected based on our qRT-PCR results and the previous data (112). However, high 
molecular weight forms of SENP1 varied between PANC-1 cells and the other cell 




The nature of detected high molecular weight forms of SENP1 is not known, however 
the N-terminus of SENP1 contains multiple phosphorylation and acetylation sites, as 
well as predicted sumoylation and ubiquitination sites (281). Our lab and others have 
found that signals in the N-terminus of SENP1 determine its subcellular distribution 
between the nucleus, cytoplasm and nuclear pore complexes (NPCs), and it is 
predicted that posttranslational modifications could affect localization (24, 282, 283). 
Since we observed variations in high molecular weight forms of SENP1 in the PANC-
1 cells by western blot, we investigated whether these correlate with changes in 
subcellular localization. We used immunofluorescence microscopy to image HPNE, 
AsPC-1 and PANC-1 cells co-stained for SENP1 and NPCs. Consistent with previous 
work from our lab (24), we found that SENP1 colocalizes with NPCs and is detectable 
at varying levels in small foci throughout the nucleoplasm in the three pancreas-
derived cell lines (Figure 18A). More specifically, we observed similar SENP1 levels 
in the nucleoplasm of AsPC-1 and PANC-1 cells, and elevated levels in the 
nucleoplasm of HPNE cells, as quantitated in Figure 18B.  
 
Bioinformatics Evaluation of SENP1 in Pancreatic Cancer Patient 
Samples  
 
To extend our studies beyond cell lines, we next evaluated SENP1 mRNA expression, 
gene alterations, and survival association in pancreatic cancer patient samples, as 
outlined in Figure 19A. We first turned to the University of California Santa Cruz 
(UCSC) Xena Public Data Hub (xena.ucsc.edu) to acquire normalized mRNA data 
from RNA sequencing studies (284) from The Cancer Genome Atlas (TCGA) (285) 
and the Genotype-Tissue Expression program (GTex) (286). TCGA is a multicenter 
effort that profiles data at the molecular level from thousands of cancer patients across 
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33 cancer types. The GTEx program is another multicenter effort that generates 
genomic and transcriptomic profiling data from over 50 types of tissues derived from 
non-cancerous patient biopsies. Importantly, there are approximately equal numbers 
of pancreatic cancer and non-cancer samples from TCGA and GTEx, respectively, 
which when normalized by Xena, allows for powerful statistical comparisons between 
the two sources of data. To that end, we compared SENP1 mRNA expression levels 
from 178 pancreatic cancer samples to 165 non-cancerous pancreatic tissue samples 
and found that SENP1 was significantly lower in the pancreatic cancer tissues as 
compared to the non-cancerous tissue (p-value < 0.05, Figure 3B). As a second 
approach, we also used the Oncomine Platform by Thermo Fisher Scientific 
(https://www.oncomine.org) (287) as an alternative data source for evaluating SENP1 
mRNA expression in pancreatic ductal adenocarcinoma tumors and matching normal 
pancreatic tissue samples by microarray (288). Here, we found that there is no 
significant difference in SENP1 mRNA expression levels between the paired tissues 
(Figure 19C). 
 
To complement our SENP1 mRNA expression data, we analyzed SENP1 gene 
alterations using the Memorial Sloan Kettering Cancer Center (MSKCC) cBioPortal 
(cbioportal.org) (289, 290) in 676 human pancreatic cancer samples. We found that 
SENP1 was amplified in 4 of the samples, deleted in 4 of the samples, and had a 
missense mutation of unknown significance in 1 sample (Figure 19D). Thus, the total 
alteration rate of the SENP1 gene in pancreatic cancer based on these samples is 
approximately 1.3%. Of that, only 0.6% (4/676) of the cases had a gene amplification. 
As a second approach, we also analyzed SENP1 single nucleotide polymorphisms 
(SNPs) in genome-wide association studies (GWAS) using the joint National Human 
Genome Research Institute (NHGRI) and European Bioinformatics Institute (EMBL-
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EBI) quality controlled and literature-derived catalog of published GWAS studies 
(https://www.ebi.ac.uk/gwas) (291). Our search identified two SENP1 variants, 
rs10875742 and rs2408955-T, associated with vital lung function and glycated 
hemoglobin levels, respectively.  
 
Lastly, to look at the association of SENP1 expression levels and pancreatic cancer 
patient survival, we used the Kaplan-Meier plotter (kmplot.com) (292) to stratify patient 
survival data based on calculated high versus low SENP1 mRNA expression levels. 
The results showed no statistically significant difference in pancreatic cancer patient 





Sumoylation regulates essential cellular processes, many of which are often 
misregulated in human cancers. As the SUMO pathway itself is also misregulated in 
numerous cancers, it has been implicated as a contributing factor in the development 
and progression of these diseases (64, 76). Researchers have found that expression 
levels of individual SUMO pathway enzymes can be used as prognostic markers for 
cancers such as prostate and cervical cancer (275, 277). Here, we used authenticated 
cell lines, validated reagents and data from large-scale genomics studies to evaluate 
the utility of SENP1 expression as a biomarker in pancreatic cancer. 
 
To explore reported SENP1 overexpression in pancreatic cancer, we first evaluated 
SENP1 mRNA levels in pancreas-derived human cell lines. We found that the normal 
control cells had significantly lower SENP1 mRNA expression as compared to the 
cancer cell lines. We also found that AsPC-1, BxPC-3 and CFPAC-1 had 
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indistinguishable differences in SENP1 expression, whereas the PANC-1 cell line had 
significantly higher levels of SENP1 expression. However, the magnitude of SENP1 
mRNA differences between cell lines did not match previously published findings 
(112). In this published study, an approximate 6-fold increase in SENP1 expression in 
the PANC-1 cell line was observed when compared to AsPC-1 cells, whereas we 
observed an approximate 2-fold increase. These differences could be due to 
differences in cell lines (our cell line identities were validated by short tandem repeat 
profiling), the use of different equipment, reagents or relative expression calculations. 
For instance, the previous report used the ΔΔCT method, whereas we used the ΔCq 
method (293) since evaluating endogenous SENP1 mRNA levels does not involve the 
use of a treatment group. Consistent with our findings, we found that our SENP1 
mRNA expression patterns were similar to those obtained by CCLE using RNA 
sequencing. Furthermore, data from CCLE revealed that elevated SENP1 mRNA 
levels in the PANC-1 cells were not associated with a gene duplication event, as all 
four pancreatic cancer cell lines were found to be diploid at the SENP1 locus. 
Surprisingly, we found that SENP1 protein levels were similar across all tested cell 
lines, despite higher mRNA expression in PANC-1 cells. This indicates that SENP1 
protein levels are regulated post-transcriptionally, possibly at the level of translation or 
protein stability. Interestingly, although SENP1 protein levels did not differ between 
cell lines, we did observe variations in predicted modified forms of SENP1 by western 
blot analysis. We also observed variations in the relative distribution of SENP1 within 
the nucleoplasm of HPNE cells in comparison to AsPC-1 and PANC-1 cells. The 
prediction that these differences in observed localization reflect differences in 
posttranslational modifications of the SENP1 N-terminus will require further study.  
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Using publicly available patient datasets, we compared SENP1 expression levels from 
hundreds of pancreatic cancer tissues to non-cancerous pancreas tissues. We found 
that SENP1 expression is lower in pancreatic cancer tissues when compared to 
unpaired-normal pancreas tissue, and is unchanged when compared to paired-
adjacent normal pancreas tissue. The difference between these two outcomes could 
be explained by tissue environment, especially considering the strong desmoplastic 
reaction that occurs in pancreatic cancer (288). It is possible that the normal-adjacent 
tissues are influenced by the tumor microenvironment (TME) (294), which in turn 
affects SENP1 mRNA expression in the surrounding tissues. These results indicate 
that SENP1 levels are highest in healthy pancreas tissues and decrease in pancreatic 
tumor tissues. This finding is in contrast to a previous observation (112) which found 
elevated SENP1 mRNA levels in pancreatic ductal adenocarcinoma tissues from 22 
patients as compared to adjacent normal tissues when assayed by qRT-PCR. These 
discordant findings could be explained by the different approaches used to evaluate 
SENP1 mRNA levels, the differences in sample sizes, or potential epidemiological 
variables related to the sources of tissue.  
 
To further explore SENP1 in patient samples, we also looked at SENP1 gene 
mutations in over 600 sequenced pancreatic cancer tissues using cBioPortal. Here, 
we found that SENP1 was amplified in 4 of the samples, deleted in 4 of the samples, 
and had a missense mutation of unknown significance in 1 sample. This amounts to a 
1.3% SENP1 gene alteration rate in pancreatic cancer, and furthermore, the observed 
differences between types of alterations suggests that SENP1 mutations in pancreatic 
cancer are not conserved. For comparison, KRAS, a protein well-known to promote 
pancreatic cancer tumorigenesis, has been found to have an alteration rate of greater 
than 90% and the alteration is almost always a single nucleotide variant (295).  
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Our search of the GWAS catalog (291) identified two SENP1 variants, rs10875742 
and rs2408955-T. The rs10875742 variant was associated with vital lung function, and 
the rs2408955-T variant was associated with hemoglobin A1c (HbA1c) at genome-
wide significance (296). Of relevance to our study, HbA1c is used to diagnose and 
monitor Type 2 diabetes (T2D), which is a risk factor and a prognostic factor for 
pancreatic cancer (297). This SENP1 variant was further classified into an erythrocytic 
group to better define its mode of action on HbA1c, however the specific effects of this 
variant on the function, structure or lifespan of red blood cells have yet to be explored. 
Given the utility of HbA1c in diagnosing and monitoring T2D, and the link between T2D 
and pancreatic cancer, this variant could be of interest for further exploration. 
 
Lastly, we found that there is no association between SENP1 expression levels and 
pancreatic cancer patient survival. Taken together, our data provides evidence that 
SENP1 is not altered at the genetic level, nor is it overexpressed in pancreatic cancer 
tissues or associated with patient survival. Thus, although a previous study has 
suggested a link between SENP1 and pancreatic cancer (112), our results do not 
support this finding. We therefore conclude that SENP1 is not likely to be an effective 
biomarker for this disease. Through this work, we have also outlined a powerful and 
freely-available bioinformatics workflow for the evaluation of potential biomarkers for 





We used authenticated cell lines, validated reagents and data from large-scale 
genomics studies to evaluate SENP1 localization, mRNA and protein level expression, 
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gene mutations and survival association in human pancreas cells and tissue samples. 
We found that SENP1 is not overexpressed in pancreatic cancer, has no association 
with patient survival and would therefore not make an effective biomarker. Through 
this work we have outlined an easy to use and freely available bioinformatics workflow 
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We received the “normal” hTERT-transformed HPNE cell line (ATCC#: CRL-4023) 
graciously from Dr. Laura Wood, and three pancreatic cancer cell lines, AsPC-1 
(ATCC#: CRL-1682), BxPC-3 (ATCC#: CRL-1687), CFPAC-1 (ATCC#: CRL-1918) 
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graciously from Dr. Scott Kern. We ordered the PANC-1 cells directly from ATCC 
(ATCC#: CRL-1469). We also used the cervical cancer cell line, HeLa (ATCC# CCL-
2), as a non-pancreas control. All cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, ThermoFisher Scientific PN: 11965118) supplemented with 
10% Fetal Bovine Serum (Atlanta Biologicals PN: S11150) and grown in a monolayer 
at 37οC and 5% CO2. Cells were passaged one to two times per week, or until cells 
reached approximately 80% confluence.  
 
All six cell lines used for this study were authenticated by the Johns Hopkins University 
(JHU) Genetic Resources Core Facility (GRCF) using the Promega GenePrint10 Short 
Tandem Repeat Profile Kit and had identities with an >80% match against the ATCC 
database. Additionally, we used the JHU GCRF to confirm that all six cell lines were 
mycoplasma free using a PCR based MycoDtect kit from Greiner Bio-One.  
 
qRT-PCR Analysis 
All six cell lines were seeded at 5.0 x 105 cells/well in a 6-well dish and grown at 37οC 
and 5% CO2 for approximately 24 hours. Total RNA was extracted using the Sigma 
GenElute Mammalian MiniPrep kit (Sigma PN: RTN10) following the vendor’s protocol. 
Extracted RNA was analyzed by nanodrop for concentration and purity. cDNA was 
generated using the New England BioLabs ProtoScript First Strand cDNA Synthesis 
Kit (NEB PN: E6300S) using 200ng of RNA, d(T)23 VN primers and following the 
vendor’s recommended protocol. The qPCR reaction was performed using Bio-Rad 
iTaq Universal SYBR Green Supermix (Bio-Rad PN: 1725121) and following the 
vendors recommended protocol. qPCR runs were performed using an Applied 
Biosystems Quant Studio with Quant Studio v1.3.1 software. Relative SENP1 
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expression was calculated using average CT values from three biological replicates, a 
validated housekeeping gene (GAPDH), and the ΔCq equation: 2-(SENP1-GAPDH). Primer 
sequences: 
 
Table 6. SENP1 and GAPDH primers used for qRT-PCR. 
 Forward Reverse 
SENP1 5'- ATCAGGCAGTGAAACGTTGGAC -3' 5'- GCAGGCTTCATTGTTTATCCCA -3' 




All six cell lines were seeded at 5.0 x 105 cells/well in a 6-well dish and grown at 37οC 
and 5% CO2 for approximately 24 hours. Cells were harvested by scraping in 100uL 
of 2X Laemmli sample buffer with 10% β-mercaptoethanol. Cells were lysed in a water 
bath sonicator for 3 x 15 second pulses, heated at 95οC for 5 minutes, cooled and 
spun at 13,000xG for 5 minutes. Samples were loaded onto a 10-well, 10% tris-glycine 
gel and run at 110V for 1 hour 15 minutes. Samples were transferred to a LF-PVDF 
membrane (Bio-Rad PN: 1704274) using the Bio-Rad TransBlot Turbo Mixed MW 
setting. Blots were blocked in 5% non-fat dry milk for 1 hour at room temperature (RT) 
with gentle shaking. Blots were then rinsed with 1X TBST and incubated overnight at 
40C with a rabbit monoclonal SENP1 antibody (abcam PN: ab108981 [1:1,000]) and a 
mouse monoclonal alpha tubulin antibody (abcam PN: ab7291 [1:15,000]) diluted in 
2% BSA, 0.02% NaN3 and 1x PBS. Blots were washed in 1xTBST and incubated in 
Goat anti-rabbit 800CW (LI-COR PN: 926-32211 [1:10,000]) and goat anti-mouse 
680LT (LI-COR PN: 926-68020 [1:10,000]) protected from light for 1 hour at RT with 
gentle shaking. Blots were imaged using the LiCor Odyssey imaging system and 
quantitated using ImageStudio v.5.2.5 software.   
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Immunofluorescence Microscopy  
Cells were seeded on coverslips at 2.5 x 105 cells/well in a 6-well dish and grown at 
37οC and 5% CO2 for approximately 24 hours. Media was carefully aspirated, cells 
were washed one time with 1x PBS, fixed in 3.5% paraformaldehyde in 1x PBS for 
7min. at RT, washed with 1x PBS and permeabilized in 0.5% Triton-X-100 in 1x PBS 
for 20min. at RT. Cells were gently washed twice with 1x PBS and primary antibodies 
were applied (SENP1 abcam PN: ab108981 [1:500]; mAb 414 abcam PN: ab24609 
[1:2,000]). Zeiss Observer Z1 fluorescence microscope with an Apotome VH optical 
sectioning grid was used to acquire images. SENP1 nucleoplasmic fluorescence 
intensity was measured using ImageJ software and graphed using RStudio.  
 
Statistical Analysis 
All statistical analyses were performed using RStudio. Differences in means for qPCR 
and western blot data were analyzed by ANOVA, followed by a Tukey Honestly 
Significant Difference test with 95% confidence intervals to identify statistically 
significant differences between sample pairs. Differences in means for the patient data 
from Xena was calculated using a Students t-test. P-values < 0.05 were considered 
significant for all reported data.  
 
 Bioinformatics: Cancer Cell Line Encyclopedia (CCLE) 
SENP1 mRNA expression and copy number data from human cancer cell lines was 
downloaded from the Broad Institute’s Cancer Cell Line Encyclopedia 
(https://portals.broadinstitute.org/ccle). Using RStudio, data was subset and graphed 




Normalized mRNA data for pancreatic cancer tissues and normal pancreas tissues 
were downloaded from the UCSC Xena public data hub (https://xena.ucsc.edu) and 
opened in RStudio. The pancreatic cancer SENP1 mRNA expression values were 
obtained from the TCGA Pancreatic Cancer (PAAD) cohort, which had 10 studies for 
a total of 196 samples. The non-cancerous SENP1 mRNA expression values were 
downloaded from the GTEX study. In RStudio, GTEx SENP1 data was subset by 
organ type to include only data from normal pancreas samples, providing a total of 167 
samples. Then, both TCGA and GTEx data sets were cleaned to remove samples with 
missing data, resulting in 178 TCGA pancreatic cancer samples, and 165 GTex normal 
samples. Lastly, normality assumptions were confirmed using the Shapiro-Wilk 
normality test and mean expression values were compared using a Students t-test and 
the results were plotted using ggplot (261). 
 
Bioinformatics: cBioPortal 
The web-based cBioPortal for Cancer Genomics (289, 290) (www.cbioportal.org) 
version 1.18.0 was used to analyze SENP1 alterations in large-scale pancreatic 
cancer genomic data sets. Three pancreatic adenocarcinoma cancer studies were 
queried: QCMG, Nature 2016 (298); TCGA, Provisional; and UTSW, Nature 
Communications 2015 (295). Molecular profiles were selected for Mutations and Copy 
Number Alterations, resulting in 751 unique patient/case sets, of which 676 were 
sequenced. The gene symbol “SENP1” was used to run the query. Presented data are 




The Thermo Fisher Scientific Oncomine platform version 4.5 (oncomine.org) was used 
to analyze SENP1 mRNA expression levels in pancreatic cancer patient samples as 
compared to adjacent normal tissues from the Badea Pancreas study (288).  
 
 
Bioinformatics: GWAS Catalog 
The web-based NHGRI-EBI Catalog of published genome-wide association studies 
(https://www.ebi.ac.uk/gwas/) was used to analyze SENP1 in GWAS studies (291). 
 
Bioinformatics: Kaplan-Meier Plotter (KM Plot) 
Relapse free and overall survival data for pancreatic cancer patients based on SENP1 
mRNA expression was analyzed using the Kaplan-Meier Plotter 
(http://kmplot.com/analysis/) using data from the pan-cancer study. The pancreatic 
ductal adenocarcinoma (n=177) study was selected and analysis was not restricted by 









Figure 17. Evaluation of SENP1 expression levels in human cell lines. A) Relative SENP1 
mRNA expression levels measured by qRT-PCR. B) Plot of SENP1 mRNA expression levels 
against SENP1 copy number in four pancreatic cancer cell lines using data from CCLE. C) 
Representative western blot image of SENP1 and tubulin signal from whole cell lysates. D) 
Quantitation of normalized SENP1 protein levels from 3 independent western blot assays. Gray 




Figure 18. SENP1 localization in pancreas-derived cells. A) Representative 
immunofluorescence microscopy images of pancreas-derived cells co-stained with antibodies 
recognizing SENP1 and NPCs (mAb 414). Scale bar is 10μm. B) Quantitation of SENP1 






Figure 19. Bioinformatics evaluation of SENP1 in pancreatic cancer patient samples. A) 
Outline of bioinformatics resources used for SENP1 analysis. B) Quantitation of SENP1 mRNA 
expression from cancerous and unpaired non-cancerous pancreas tissue using data from the 
UCSC Xena Public Data Hub. C) SENP1 mRNA expression levels in paired-normal pancreas 
tissue as compared to cancer tissue samples using Oncomine. D) Oncoprint of SENP1 gene 
alterations in 676 patient samples using cBioPortal. E) Kaplan-Meier survival analysis of 261 
patients with high versus low SENP1 expression analyzed using KMPlot.com. Hazard ratio 



























There is growing evidence that SUMO pathway components contribute to many 
diverse human diseases. The SUMO paralogs in particular regulate hundreds of 
proteins involved in a wide-range of processes that are associated with cancer, 
neurodegeneration and auto-immune disorders, among others. Questions 
surrounding the unique roles of the SUMO paralogs in these diverse cellular processes 
however, remain unanswered. Do the paralogs have unique and non-redundant roles, 
which could help explain the vast array of cellular functions regulated by sumoylation? 
If so, how is this paralog-specificity itself regulated? Moreover, could we 
therapeutically target different paralogs in the pathway? And if so, how might we 
identify the best patients for such a treatment? The work presented in this thesis uses 
a multi-faceted approach to address these questions. We first reviewed the literature 
for evidence of paralog-specific functions, where we found examples ranging from 
regulation of individual proteins to entire cellular processes. We then generated 
SUMO1 and SUMO2 knockout (KO) cells and systematically analyzed them for 
paralog-specific functions. This analysis revealed non-redundant roles for the paralogs 
in regulating cellular morphology, the cellular stress response, nuclear body integrity 
and gene expression. Lastly, we developed a bioinformatics workflow to analyze 
SUMO pathway enzyme expression levels in cancerous tissues as compared to 
normal human tissues. We used this workflow and found that the SENP1 SUMO 
protease is not a predictive biomarker of pancreatic cancer. Collectively, we have 
identified unique and non-redundant roles for the SUMO paralogs, and have provided 




SUMO Paralog-Specific Functions 
 
As presented in Chapter 2, we compiled findings from published studies that explored 
SUMO paralog-specific functions. Two overarching themes that emerged from this 
review were that the SUMO paralogs have conserved functions in mediating specific 
protein-protein interactions, and that biological outcomes of SUMO-modified proteins 
are complex and often context dependent. Beyond these themes, evidence of paralog-
specific differences are abundant, and supported by the unique sets of proteins that 
are selectively modified by different paralogs. Moreover, evidence of paralog-specific 
conjugating and deconjugating enzymes suggest mechanisms for differential 
regulation of paralog-specific functions. 
 
In Chapter 3, we provided evidence that SUMO1 and SUMO2 have non-redundant 
functions in regulating a host of cellular processes, including control of gene 
expression. Moving beyond a description of phenotypes and exploring the underlying 
molecular basis of changes observed in SUMO1 and SUMO2 KO cells will require a 
more comprehensive analysis of paralog specific substrates, both on and off 
chromatin. Proteomics experiments have identified a limited number of unique SUMO1 
and SUMO2/3 substrates, however, the most recent paralog-specific studies were 
done almost ten years ago (19, 172, 173). Now that more advanced and sensitive 
mass spectrometry technologies are available, there is an opportunity to conduct a 
modern and systematic analysis of paralog-specific substrates (19). An ideal 
experimental design includes the use of paralog-specific antibodies to identify 
endogenously modified substrates by mass spectrometry, and then coupling this data 
with chromatin-immunoprecipitation and sequencing analysis. In conjunction with our 
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current RNA-sequencing data, this combination of results would provide a 
comprehensive view of what the SUMO paralogs are doing in cells, at the level of gene 
and protein regulation. In addition to identifying unique SUMO1 or SUMO2/3 modified 
substrates, it will also be important to consider overlapping substrates since the effects 
of paralog-specific modification can differ, as shown with CFTR and IΚBα (71, 184, 
225).  
 
How is substrate-specificity by the paralogs achieved? Two primary mechanisms were 
revealed through our analysis of the literature. First, differences in the SUMO 
interacting motif (SIM) binding domain between SUMO1 and SUMO2/3 play a role in 
determining paralog-specific modifications (48). For instance, DAXX and BLM are 
preferentially modified by SUMO1 and SUMO2/3, respectively. This is dictated through 
paralog-specific non-covalent interactions with these substrates that subsequently 
promotes covalent modification (188, 189, 191, 195). Since this has been observed 
for multiple SUMO1 and SUMO2/3 specific substrates, it is likely a common 
mechanism of paralog-specific modification. Secondly, some of the SUMO pathway 
enzymes display preferences for specific paralogs, as observed by SENP6 which 
preferentially hydrolyzes polymeric-SUMO2/3 chains (32). Understanding these 
mechanisms in greater detail is important given our evidence that the SUMO paralogs 
have unique functions in regulating a vast array of cellular functions. The next 
questions to ask include, how can the same SIM binding domains mediate interactions 
with so many diverse substrates, and is there a way to characterize the functional 
outcomes? For instance, lysine and arginine residues exist in the SIM binding domain 
of both SUMO1 and SUMO2/3, however they selectively provide SUMO2/3 with the 
ability to strongly repress transcription (54). Beyond its role in transcription, the 
SUMO2/3 SIM binding domain is also involved in mediating protein-protein 
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interactions between DNA repair factors, and kinetochore-associated proteins during 
mitosis (188, 198). Thus, it remains to be answered how this single domain can impart 
paralog-specific interactions with so many functionally diverse proteins. Of note, it’s 
possible that varying polymeric-SUMO2/3 chain lengths may have important roles in 
mediating this specificity, but this too requires further study. 
 
Future Directions to Evaluate Paralog-Specific Functions  
 
In Chapter 3 we presented our systematic analysis of SUMO KO cell lines, which 
provided evidence for paralog-specific functions in regulating cellular morphology, the 
cellular stress response, nuclear body integrity and gene expression. The findings 
from this study revealed many questions, such as, what are the effects of SUMO2 on 
the cytoskeleton and regulatory pathways that control cell morphology? How do 
SUMO1 and SUMO2 individually sensitize cells to treatment with hydroxyurea? What 
are the targets and consequences of SUMO1 and SUMO2 modification on proteins 
localized to PML-NBs? Do SUMO1 and SUMO2 mediate association of transcription 
factors with unique regulatory proteins at gene promoters? How is expression of 
different genes specifically regulated by SUMO1 or SUMO2? These questions 
represent exciting new directions for future investigation. For instance, we are 
intrigued by the finding that a significant number of histone genes were specifically up-
regulated in the SUMO2 KO cells, and had a corresponding decrease in SUMO1 KO 
cells. What is particularly peculiar about this finding is that although histone genes are 
localized to three histone gene loci, only a subset of the genes in these loci were 
changed (Figure 20). How are the SUMO paralogs selectively affecting the expression 
of only some histone genes? How is SUMO2 repressing their activation in WT cells, 
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and conversely, what is the mechanism behind SUMO1 activation of these histone 
genes? As similar trends were observed for immune response genes, uncovering this 
mechanism could contribute to our general understanding of SUMO-regulated gene 
expression in other cellular contexts. 
 
To begin to understand the paralog-specific mechanisms driving the phenotypes 
described in Chapter 3, future studies need to be performed in WT cells. For instance, 
to better understand the effects of SUMO1 and SUMO2 on histone gene expression, 
it would be helpful to identify sumoylated substrates that are involved in this process 
in WT cells. Of note, to more generally understand how SUMO1 and SUMO2/3 are 
uniquely regulating transcription, we have performed Assay for Transposase-
Accessible Chromatin using sequencing (ATAC-seq) on our U2OS WT and SUMO KO 
cells. Based on our RNA-seq analysis where we identified thousands of uniquely 
differentially expressed genes in the SUMO KO cells, we hypothesize that there will 
be many differences in accessible chromatin regions between the cell lines that 
correlate with affected genes. This finding would provide evidence that loss of the 
SUMO paralogs is associated with varying changes in the chromatin landscape, 
thereby suggesting that the SUMO paralogs uniquely regulate chromatin remodeling 
factors. Whether this regulation is through paralog-specific modification of unique 
factors, or through differing effects of the paralogs on shared modifiers will require 
further study, again in WT cells. 
 
Lastly, we are interested in understanding what molecular attributes of the SUMO 
paralogs are required for the unique and non-redundant phenotypes reported in 
Chapter 3. We could explore these attributes by performing rescue experiments with 
targeted SUMO1 and SUMO2 mutants (Figure 21). For instance, to see whether 
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effects on transcription are dependent on SUMO conjugation, we could generate 
SUMO paralogs that do not have the di-glycine motif required for activation and 
conjugation onto target proteins. Moreover, we could generate mutants with defective 
SIM binding domains, and for SUMO2/3, mutants that lack the K11 internal 
sumoylation site that facilitates chain formation. Using our established qRT-PCR 
method, we could easily assay for effects of such mutants on gene expression. Lastly, 
it should be mentioned that in addition to doing these studies in U2OS cells for 
consistency and reproducibility, it will also be advantageous to use other human cell 
lines to demonstrate conservation of phenotypes. Identification of potentially 
interesting cell lines could be aided by the use of bioinformatics, as discussed in the 
following section.   
 
Exploration of the SUMO Pathway Using Bioinformatics 
 
 
Using bioinformatics, we developed a pipeline for evaluating SUMO pathway enzyme 
misregulation in human cancers. Beyond using this workflow to identify cancers with 
misregulated sumoylation, we can also use bioinformatics to learn about sumoylation 
more generally. For instance, the Genotype Expression (GTEx) project has gene 
expression data from over 15,000 human samples taken from 54 different non-
cancerous tissues (https://www.gtexportal.org). Importantly, the data are annotated 
with patient attributes and thus it will be interesting to use this data and ask whether 
there is an association between the SUMO pathway components with age, sex or 
cause of death overall, and in specific tissues. Moreover, data portals such as 
cBioPortal (299), COSMIC (300) and TCGA (https://www.cancer.gov/tcga) contain a 
wealth of mutational information at the gene and protein levels from human cancer 
patient samples. Thus, it would also be interesting to mine data from these repositories 
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and ask whether the paralogs or pathway enzymes are misregulated in a particular 
cancer. Furthermore, we could ask if there are mutations that are associated with poor 
disease progression or prognosis. We could then study the biological consequences 
of such mutations in the lab. In summary, the questions that can be both asked and 
answered with the available data are seemingly endless, thereby opening many doors 
for further exploration. 
 
The SUMO Pathway as a Therapeutic Target and a Biomarker 
 
The work in this thesis highlights many of the essential biological processes that are 
regulated by the SUMO pathway. Misregulation of these processes is often reported 
in many human diseases, thereby implicating sumoylation in their onset and 
progression. As such, pharmaceutical companies have developed a SUMO E1 
inhibitor, TAK-981, that is currently in clinical trials for cancer therapy, and 
interestingly, also for COVID-19 treatment (140-143). It will be interesting to see the 
results of these Phase I studies, which are evaluating the safety and tolerability of 
TAK-981 using dose escalation studies in human patients.  
 
Given that a SUMO-pathway targeting drug has been developed, and hopefully will 
prove to be safe and effective, it would also be advantageous to have a biomarker for 
predicting the success of this drug in potential patients. Although we found that the 
SENP1 SUMO protease is not an effective biomarker for pancreatic cancer (Chapter 
4), we are still interested in whether differential expression of SUMO pathway enzymes 
could be an indicator of success for a SUMO inhibitor. More specifically, are tissues 
or cells with elevated levels of SUMO proteases more sensitive to treatment with a 
SUMO inhibitor? To begin to address this question, we have established optimal 
 158 
concentrations to obtain varying levels of SENP2 using tetracycline-inducible SENP2 
expressing cells (Figure 22A). We have obtained a pre-clinical SUMO E1 inhibitor that 
is available for research use, and now need to determine the EC50 value of this drug 
in our SENP2 expressing cell line (197). We can then test the hypothesis that cells 
with the highest levels of the SUMO protease will be more sensitive to the drug, since 
they have the lowest levels of SUMO-conjugated proteins, as demonstrated through 
overexpressing SENP1 in HeLa cells (Figure 22B). Results from this study would 
provide evidence for or against the use of SUMO proteases as biomarkers for 
treatment with a SUMO inhibitor.  
 
In summary, we have provided evidence that SUMO1 and SUMO2 have unique roles 
in regulating proteins associated with many human diseases. Our work provides a 
foundation for future medical and scientific SUMO-focused endeavors aimed at better 
understanding the contributions of sumoylation to health and disease and providing 






Figure 20. Labeled karyoplot of all histone genes. Histone genes are categorized into three 
distinct groups, as labeled, and localized to 3 predominant loci on human Chromosomes (Chr) 
1 and 6. Genes that were changed in SUMO KO cells (from our RNA-seq data) are highlighted. 
The question remains to be answered about how only select and seemingly random histone 









Figure 21. Targeted SUMO mutants for future mechanistic studies. Surface models of 
SUMO1 (PDB: 1A5R.A) and SUMO2 (PDB: 2N9E.B) showing targeted mutations (labeled), 




Figure 22. Varying levels of SUMO proteases in cell culture. A) Varying levels of SENP2 
can be induced in HEK-293 cells, demonstrating a proof of concept method for directly testing 
the sensitivity of cancer cell lines with varying levels of SUMO proteases to treatment with 
sumoylation inhibitors. B) Preliminary data showing that increasing levels of SENP1 lead to a 
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